GARY L. WENK
OFFICE ADDRESS Department of Psychology
Ohio State University
1835 Neil Avenue, Room 047
Columbus, OH 43210
Email: wenk.6@osu.edu
Tx: 614) 688-3404
Fax: (614) 688-4733
EDUCATION
Ph.D.
1980
University of Cincinnati, Cincinnati, Ohio.
Neurotoxicology
B.A.
1975
Albion College, Albion, Michigan.
Psychology & Biology (with honors)
ACADEMIC AND PROFESSIONAL EXPERIENCE
2008 – Pres Arts & Sciences Faculty Advisory Council, Ohio State University.
2008 – Pres Chairperson, Exceptional, Unconventional Research Enabling Knowledge
Acceleration (EUREKA) Special Review Board for NIA, NINDS, NIGMS, NIMH,
NIDA, for the National Institutes of Health.
2008 – 2010 Chartered Member, Aging Systems and Geriatrics Study Section, Center for
Scientific Review, National Institutes of Health.
2008 – Pres Promotion & Tenure Committee, Department of Psychology, Ohio State
University.
2006 – 2012 Co-Chair, Neurodegenerative/Dementia Disease State Taskforce of the
Neurosciences Signature Program, Ohio State University.
2007 – Pres Peer Review Committee, Department of Psychology, Ohio State University.
2006 – Pres Center for Brain and Spinal Cord Repair, Ohio State University, Associate
Member.
2005 – Pres Professor, Departments of Psychology & Neuroscience & Molecular
Virology, Immunology and Medical Genetics, Ohio State University.
2005 – Pres Faculty, Neuroscience Graduate Studies Program, Ohio State University College
of Medicine.
Wenk
2
2003 – 2004 Chair, Clinical Neuroscience and Disease Study Section, National Institutes of
Health, Washington, D.C.
2002 – 2003 Chair, Brain Disorders and Clinical Neuroscience –1 Study Section, National
Institutes of Health, Washington, D.C.
2002 – 2005 Gerontology Graduate Interdisciplinary Program Faculty, University of Arizona,
Tucson, Arizona.
2001 – 2003 Chair, Curriculum Committee, University of Arizona College of Medicine, Tucson,
Arizona.
2001 – 2002 Promotion & Tenure Committee, Department of Psychology, University of Arizona,
Tucson, Arizona.
2001 – 2002 Research Committee for the Arizona Center on Aging, Center of Excellence,
Arizona Health Sciences Center, Tucson, Arizona.
2001 – 2005 Center Member, Center on Injury Mechanisms and Related Responses, University
of Arizona College of Nursing, Tucson, Arizona.
2000 – 2001 Committee on Academic Freedom and Tenure, University of Arizona, Tucson,
Arizona.
2000 – 2001 Chair, Social and Behavioral Sciences Standing Subcommittee, Curriculum
Committee, University of Arizona College of Medicine, Tucson, Arizona.
2000 – 2003 Curriculum Committee, University of Arizona College of Medicine, Tucson,
Arizona.
1997 –2004 Chartered Member, Brain Disorders and Clinical Neuroscience –1, National
Institutes of Health, Washington, D.C.
1996 – 2005 Professor, Departments of Psychology and Neurology, University of Arizona,
Tucson, Arizona.
1998 – 1999 Principles of Clinical Medicine Clerkship Review Committee, ViceChair, University of Arizona, Tucson, Arizona.
1996 – 2005 Autism Think Tank Group, Autism Research Foundation, Harvard
University, Boston, Massachusetts.
1995 – 1998 Obstetrics and Gynecology Clerkship Review Committee, University
of Arizona, Tucson, Arizona.
Wenk
3
1991 – 1999 Committee on Neuroscience, Graduate Student Progress Committee, University
of Arizona, Tucson, Arizona.
1996 – 1998 Graduate Committee, Department of Psychology, University of Arizona,
Tucson, Arizona.
1994 -1995 Research Priorities Committee - Biology 21 Heads
1993 - 1995 Executive Committee of the Committee on Neuroscience.
1992 - 1995 Director, Graduate Program in Biopsychology, Department of Psychology,
University of Arizona, Tucson, Arizona.
1990 - 1995 Associate Professor (Tenured), Departments of Psychology and Neurology,
University of Arizona, Tucson, Arizona.
1990 - 2005 Research Scientist in Arizona Research Laboratories, Division of Neural Systems,
Memory and Aging.
1989 - 1990 Program Director, Neurobiology of Learning and Memory, Biological Basis of
Behavior Program, Division of Behavioral and Neural Sciences, National Science
Foundation, Washington, D.C.
1989 - 1990 Director of the Advisory Committee of the Biological Sciences Directorate of the
National Science Foundation, Washington, D.C.
1988 - 1990 Research Scientist, Department of Psychology, Neuromnemonics Laboratory,
The Johns Hopkins University, Baltimore, Maryland.
1988 - 1990 Associate Professor, Department of Psychology, The Johns Hopkins University,
Baltimore, Maryland.
1983 - 1988 Instructor, School of Continuing Studies, The Johns Hopkins University, Baltimore,
Maryland.
1982 - 1988 Associate Research Scientist, Department of Psychology, Neuromnemonics
Laboratory, The Johns Hopkins University, Baltimore, Maryland.
1985 - 1988 Assistant Professor, Department of Psychology, The Johns Hopkins University,
Baltimore, Maryland.
1981 - 1982 NIH Postdoctoral Fellow, Department of Neuropathology (with Dr Peter Davies &
Robert Terry), Albert Einstein College of Medicine, Bronx, New York.
Wenk
4
ADVISORY POSITIONS
Editorial Board Membership:
Psychobiology, 1993 - 2003.
Behavioral Neuroscience, 1994 – 1995
Journal of Neuroinflammation, 2003- Pres.
Drug Discovery Today: Disease Models, 2004 – 2009.
Frontiers in Aging Neuroscience, 2009 – Pres.
Reviewer for the Following Journals: Aging Cell, Annals of Neurology, Behavioral
and Neural Sciences, Behavioral and Neural Biology, Behavioral Neuroscience,
Behavioral Brain Research, Biochemical Pharmacology, Brain Research, Cerebral
Cortex, European Journal of Neuroscience, Experimental Brain Research, Gerontology,
Journal of Pharmacology, Journal of Pharmacology and Experimental Therapeutics,
Journal of Neuroscience, Journal of Neurochemistry, Journal of Neuroinflammation,
Journal of Neurodegeneration, Learning & Memory, Life Sciences, Neurobehavioral
Toxicology and Teratology, Neurobiology of Aging, Neuroscience, Neuroscience and
Biobehavioral Reviews, Neurotoxicology, Journal of Comparative Neurology,
Pharmacology, Biochemistry & Behavior, Physiology & Behavior, Proceedings of the
National Academy of Sciences, Psychobiology, Psychopharmacology, Science.
Grant Adjudication for: Alzheimer's Disease and Related Disorders Foundation,
Department of the Navy, International Human Frontier Science Program, International
Science Foundation, National Science Foundation, New Zealand Neurological
Foundation, Ontario Mental Health Foundation, United States-Israel Binational Science
Foundation, Alzheimer Society of Canada, Veteran's Administration, National Institute
of Aging Ad-Hoc Site Visit Committee for Alzheimer's Disease Research Centers,
Internationale Stichting Alzheimer Onderzoek, Netherlands, Neurological Sciences and
Disorders A, Biology of Development and Aging Integrated review group, Integrative
Functional and Cognitive Neuroscience Integrated review group, Clinical Neuroscience
and Disease, Brain Disorders and Clinical Neuroscience, Aging Systems and Geriatrics
(8), Committee on Research and Development of The Hong Kong Institute of Education
(1), French National Research Agency (4).
Expert Consultant: Burroughs Wellcome Pharmaceutical Co. (NC), American Hoechst,
Inc. (NJ), Gliatech, Inc. (OH), Merz Pharmaceuticals (Germany), Sigma Tau
Pharmaceutical Co. (Italy), Otsuka Pharmaceutical Co. (Japan), Sinauer Publishers
(CT), Judge - International Science and Engineering Fair (1996), Cephalon Inc. (PA),
Janssen Pharmaceuticals (NJ), NiCox S.A. (France), Parke-Davis, Warner-Lambert Co.
(MI), ABC News (NY), Forest Laboratories (NY), CTG Pharma (Milan).
TEACHING EXPERIENCE
Brain and Behavior; Physiological Psychology; Psychopharmacology; Introductory
Wenk
5
Statistics; Advanced Statistics; Business Statistics; Algebra & Trigonometry; Inorganic
Chemistry; Introduction to Biopsychology; Drugs, Brain & Behavior; Brain, Behavior &
Computation; Human Neuroscience; Drugs and the Brain; Herbal Drugs and the Brain;
Drugs and Modern Society, Behavioral Neuroscience, Introduction to
Psychopharmacology.
TRAINING EXPERIENCE
Post-Doctoral Fellows: Donna Hughey, Ph.D.; Linda Gorman, Ph.D.; James
Stoehr, Ph.D.; Beatrice Hauss-Wegrzyniak, Ph.D.; Susanna Rosi, Ph.D.;
Yannick Marchalant, Ph.D.; Francesca Cerbai, Ph.D.; Isabelle Bardou, Ph.D.,
Linda Adzovic, Ph.D.
Doctoral Candidates: David Hepler; Cheryl Harrington; George Quintana; Lauren Baker
Willard; Lisa Marriott; Holly Brothers; Sarah Hopp.
SOCIETY MEMBERSHIPS
American Society for Neurochemistry, Gerontological Society of America, International
Society for Neurochemistry, International College of Geriatric
Psychoneuropharmacology, Sigma Xi, Academy of Kettering Fellows of the University
of Cincinnati, New York Academy of Sciences, Society for Neuroscience, International
Brain Research Organization, American Association for the Advancement of Science,
American Psychological Society, Neurotoxicity Society.
TEACHING HONORS
University of Arizona College of Medicine, Year 1 Outstanding Achievement in
Teaching in the Basic Sciences Award, for Human Neuroscience.
Vernon and Virginia Furrow Excellence in Teaching Award, University of Arizona School
of Medicine, April, 1995.
Five Star Faculty Teaching Award, University of Arizona, May, 1999.
Distinguished Teaching Award, Ohio State University, 2011.
RESEARCH HONORS
Fellow, American Association for the Advancement of Science, 2008.
College of Social and Behavioral Sciences Joan N. Huber Faculty Fellowship Award,
2009
Wenk
6
Harlan Hatcher Arts and Sciences Distinguished Faculty Award, 2012
The Ohio State University Women & Philanthropy Award, 2012.
PUBLICATIONS
Wenk, G. & Greenland, R. (1980) An investigation of the performance of a high pressure liquid
chromatography system with an electrochemical detector. Journal of Chromatography, 183:
261-267.
Wenk, G. & Stemmer, K. (1981) The influence of ingested aluminum upon norepinephrine and
dopamine levels in the rat brain. Neurotoxicology, 2: 347-353.
Wenk, G. & Stemmer, K. (1982) Activity of the enzymes dopamine--hydroxylase and
phenylethanolamine-N-methyltransferase in discrete brain regions of the rat following
aluminum ingestion. Neurotoxicology, 3: 93-99.
Wenk, G. & Suzuki, K. (1982) The effect of copper supplementation on the brain copper
concentration of the brindled mouse. Biochemical Journal, 205: 485-487.
Wenk, G. & Suzuki, K. (1983) Congenital copper deficiency: copper therapy and
dopamine--hydroxylase activity in the mottled (brindled) mouse. Journal
of Neurochemistry, 41: 1648-1652.
Wenk, G. & Stemmer, K. (1983) Suboptimal dietary zinc increases aluminum accumulation in
rat central nervous system. Brain Research, 288: 393-395.
Wenk, G. & Olton, D. (1984) Recovery of neocortical choline acetyltransferase following
ibotenic acid injection into the nucleus basalis magnocellularis in rats. Brain Research, 293:
184-186.
Wenk, G., Hepler, D. & Olton, D. (1984) The influence of behavior on (3H)-choline uptake into
acetylcholinergic neurons of the nucleus basalis magnocellularis and the medial septal
area. Behavioral Brain Research, 13: 129-138.
Wenk, G., Cribbs, B. & McCall, L. (1984) Nucleus basalis magnocellularis: Optimal coordinates
for selective reduction of choline acetyltransferase. Experimental Brain Research, 56:
335-340.
(10)Wenk, G. (1984) Pharmacological manipulations of the substantia innominata-cortical
cholinergic pathway. Neuroscience Letters, 51: 99-103.
Wenk
7
Hepler, D., Olton, D., Wenk, G. & Coyle, J. (1985) Lesions of the nucleus basalis
magnocellularis and medial septal area of rats produce qualitatively similar memory
impairments. Journal of Neuroscience, 5: 866-873.
Hepler, D., Wenk, G., Olton, D. & Coyle, J. Lesions in nucleus basalis magnocellularis and
medial septal area of rats produce similar memory impairments in appetitive and
non-appetitive behavioral tasks. In: D.S. Olton, E. Gamzu, & S. Corkin, (Eds.), Memory
Dysfunctions: An Integration of Animal and Human Research From Preclinical and Clinical
Perspectives, N.Y. Acad. Sci. Press, New York. 1985, pp. 518-519.
Knowlton, B., Wenk, G., Olton, D. & Coyle, J. (1985) Basal forebrain lesions produce a
dissociation of trial dependent and trial independent memory performance. Brain Research,
345: 315-321.
Hepler, D.J., Wenk, G.L., Cribbs, B.L., Olton, D.S. & Coyle, J.T. (1985) Memory impairments
following basal forebrain lesions. Brain Research, 346: 8-14.
Wenk, G. Pharmacological regulation of the substantia innominata-neocortical cholinergic
pathway. In: D.S. Olton, E. Gamzu & S. Corkin, (Eds.), Memory Dysfunctions: An
Integration of Animal and Human Research From Preclinical and Clinical Perspectives,
N.Y. Acad. Sci. Press, New York. 1985, pp. 541-542.
Wenk, G. & Olton, D. Lesion analysis as a tool in neurobehavioral toxicology. In: Z. Annau,
(Ed.), Behavioral Toxicology, Johns Hopkins University Press, Baltimore. 1986, pp. 268276.
Meck, W.H., Church, R.M. & Wenk, G.L. (1986) Arginine vasopression innoculates against
age-related changes in sodium-dependent high affinity choline uptake and discrepancies in
the content of temporal memory. European Journal of Pharmacology, 130: 327-331.
Wenk, G.L., Engisch, K.L., McCall, L.D., Aigner, T.G., Mitchell, S.J., Struble, R.L., Price, D.L. &
Olton, D.S. (1986) [3H]Ketanserin (serotonin2) binding increases in monkey cortex following
basal forebrain lesions with ibotenic acid. Neurochemistry International, 9: 557-562.
Wenk, G.L. & Engisch, K.L. (1986) [3H]Ketanserin (serotonin2) binding increases in rat cortex
following basal forebrain lesions with ibotenic acid. Journal of Neurochemistry, 47: 845850.
(20)Wenk, G., Sweeney, J., Hughey, D., Carson, J. & Olton, D. (1986) Choline acetyltransferase inhibition does not impair radial maze performance in rats. Pharmacology,
Biochemistry and Behavior, 25: 521-526.
Olton, D.S., Wenk, G.L. & Pontecorvo, M.J. (1986) Cognitive enhancers: Experimental
strategies and results. Clinical Neuropharmacology, 9: 295-297.
Wenk
8
Wenk, G.L. (1987) The basal forebrain cholinergic system and memory. International Journal of
Neuroscience, 31: 420.
Wenk, G.L., Hughey, D., Boundy, V., Kim, A., Walker, L. & Olton, D.S. (1987) Neurotransmitters
and memory: The role of cholinergic, serotonergic and noradrenergic systems. Behavioral
Neuroscience, 101: 325-332.
Aigner, T.G., Mitchell, S.J., Aggleton, J.P., DeLong, M.R., Struble, R.G., Price, D.L., Wenk, G.L.
& Mishkin M. (1987) Effects of scopolamine and physostigmine on recognition memory in
monkeys with ibotenic-acid induced lesions of the nucleus basalis of Meynert.
Psychopharmacology, 92: 292-300.
Raffaele, K., Hughey, D., Wenk, G., Olton, D., Modrow, H. & McDonough, J. (1987) Long term
behavioral changes in rats following organophosphate exposure. Pharmacology,
Biochemistry and Behavior, 27: 407-412.
D'Amato, R.J., Zweig, R.M., Whitehouse, P.J., Wenk, G.L., Singer, H.S., Mayeux, R., Price,
D.L. & Snyder, S.H. (1987) Aminergic systems in Alzheimer's and Parkinson's disease:
marked damage to serotonin neurons. Annals of Neurology, 22: 229-236.
Hohmann, C.F., Wenk, G.L., Lowenstein, P., Brown, M. & Coyle, J.T. (1987) Age-related
reoccurrence of lesion-induced basal forebrain cholinergic deficits. Neuroscience Letters,
82: 253-259.
Wenk, G.L. & Olton, D.S. Basal forebrain cholinergic neurons and Alzheimer's disease. In:
J.T. Coyle, (Ed.), Animal Models of Dementia: A Synaptic Neurochemical Perspective, Vol
33: Neurology and Neurobiology, Alan R. Liss, New York. 1987, pp. 81-101.
Wenk, G.L., Olton, D.S., Hughey, D. & Engisch, K. (1987) Animal models of cholinergic
dysfunction related to aging and senile dementia. Gerontology, 33: 277.
(30)Meck, W.H., Church, R.M., Wenk, G.L. & Olton, D.S. (1987) Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. Journal
of Neuroscience, 7: 3505-3511.
Olton, D.S. & Wenk, G.L. Dementia: Animal models of the cognitive impairments produced by
degeneration of the basal forebrain cholinergic system. In: H.Y. Meltzer, (Ed.),
Psychopharmacology: The Third Generation of Progress. Raven Press, New York. 1987,
pp. 941-953.
Wenk, G.L., Cork, L.C. & Olton D.S. Behavioral effects of age-related degeneration in the
acetylcholinergic and serotonergic neural systems in monkeys and rats. In: G. Pepeu, B.
Tomlinson & C.M. Wischik, (Eds.), New Trends in Aging Research, Vol. 15, Liviana Press,
Italy, 1988, pp. 91-100.
Wenk
9
Olton, D.S., Wenk, G.L., Church, R.M. & Meck, W.H. (1988) Attention and the frontal cortical
cortex as examined by simultaneous temporal processing. Neuropsychologia, 26: 307-318.
Peternel, A., Hughey, D., Wenk, G. & Olton, D. (1988) Basal forebrain and memory: Neurotoxic
lesions impair serial reversals of a spatial discrimination. Psychobiology, 16: 54-58.
Olton, D.S. & Wenk, G.L. Animal models to investigate the role of NMDA receptors in learning
and memory. In: E.A. Cavalheiro, J. Lehmann & L. Turski, (Eds.), Frontiers in Excitatory
Amino Acid Research, Vol. 46: Neurology and Neurobiology, Alan R. Liss, New York, 1988,
pp. 379-384.
Wenk, G. & Rokaeus, A. (1988) Basal forebrain lesions differentially alter galanin levels and
acetylcholinergic receptors in the hippocampus and neocortex. Brain Research, 460: 1721.
Wenk, G.L. (1988) Amnesia and Alzheimer's disease: Which neurotransmitter system is
responsible? Neurobiology of Aging, 9: 640-641.
Szigethy, E., Wenk, G.L. & Beaudet, A. (1989) Anatomical substrate for neurotensin-acetylcholine interactions in the rat basal forebrain. Peptides, 9: 1227-1234.
Markowska, A.L., Stone, W.S., Ingram, D.K., Reynolds, J., Gold, P.E., Conti, L.H., Pontecorvo,
M.J., Wenk, G.L. & Olton, D.S. (1989) Individual differences in aging: Behavioral and
neurobiological correlates. Neurobiology of Aging, 10: 31-43.
(40)Wenk, G.L., Pierce, D.J., Struble, R.G., Price, D.L. & Cork, L.C. (1989) Age-related
changes in multiple neurotransmitter systems in the monkey brain. Neurobiology of Aging,
10: 11-19.
Atack, J.R., Wenk, G.L., Wagster, M.V., Kellar, K.J., Whitehouse, P.J. & Rapoport, S.I. (1989)
Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following
unilateral lesions of the rat nucleus basalis magnocellularis: An autoradiographic study.
Brain Research, 483: 367-372.
Wenk, G.L., Grey, C.M., Ingram, D.K., Spangler, D.L. & Olton, D.S. (1989) Retention of maze
performance inversely correlates with N-methyl-D-aspartate receptor number in
hippocampus and frontal neocortex in rat. Behavioral Neuroscience, 103: 688-690.
Crawley, J.N. & Wenk, G.L. (1989) Coexistence of galanin and acetylcholine: Is galanin
involved in memory processes and dementia? Trends in Neurosciences, 12: 278-282.
Wenk, G.L., Markowska, A.L. & Olton, D.S. (1989) Basal forebrain lesions and memory:
Alterations in neurotensin, not acetylcholine, may cause amnesia. Behavioral
Neuroscience, 103: 765-769.
Wenk
10
Wenk, G.L. (1989) An hypothesis on the role of glucose in the mechanism of action of cognitive
enhancers. Psychopharmacology, 99: 431-438.
Wenk, G.L. & Olton, D.S. (1989) Cognitive enhancers: potential strategies and experimental
results. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(Suppl): S117S139.
Wenk, G.L. Nutrition - cognition and memory. In: R.B. Weg, (Ed.), Topics in Geriatric
Rehabilitation, Vol 6: Nutrition and Rehabilitation, Aspen Publishers, Rockville, MD, 1989,
pp. 79-87.
Olton, D.S. & Wenk, G.L. (1990) The development of behavioral tests to assess the effects of
cognitive enhancers. Pharmacopsychiatry, 23 (Suppl): 65-69.
Price, D.L., Koo, E.H., Wagster, M.V., Walker, L.C., Wenk, G.L., Applegate, M.D., Kitt, C.A. &
Cork, L.C. Behavioral, cellular, and molecular biological studies of aged nonhuman
primates. In: R.J. Wurtman, S. Corkin, J.H. Growdon & E. Ritter-Walker, (Eds.), Advances
in Neurology, Vol. 51: Alzheimer's Disease, Raven Press, Ltd., New York, 1990, pp. 83-89.
(50)Naidu, S., Hyman, S., Piazza, K., Savedra, J., Perman, J., Wenk, G., Kitt, C., Troncoso, J.,
Price, D., Cassanova, M., Miller, D., Thomas, G., Niedermeyer, E. & Moser, H. (1990) The
Rett syndrome: Progress report on studies at the Kennedy Institute. Brain and
Development, 12: 5-7.
Spangler, E.L., Wenk, G.L., Chachich, M.E., Smith, K. & Ingram, D.K. (1990) Complex maze
performance in rats: Effects of noradrenergic depletion and cholinergic blockade.
Behavioral Neuroscience, 104: 410-417.
Markowska, A.L., Wenk, G.L. & Olton, D.S. (1990) Nucleus basalis magnocellularis and
memory: loss of cholinergic neurons may not impair non spatial nor spatial memory.
Behavioral and Neural Biology, 54: 13-26.
Sakurai, Y. & Wenk, G.L. (1990) The interaction of acetylcholinergic and serotonergic systems
on performance in a continuous non-matching to sample task. Brain Research, 519: 118121.
Wenk, G.L. (1990) Animal models of Alzheimer's disease: Are they valid and useful? Acta
Neurobiologiae Experimentalis, 50: 219-223.
Stone, W.S., Wenk, G.L., Olton, D.S. & Gold, P.E. (1990) Poor blood glucose regulation
predicts sleep and memory deficits in normal aged rats. Journal of Gerontology, 45: B169173.
Wenk, G.L., Walker, L.C., Price, D.L. & Cork, L.C. (1991) Loss of NMDA, but not GABA-A,
binding sites in brains of aged rats and monkeys. Neurobiology of Aging, 12: 93-98.
Wenk
11
Markowska, A.L. & Wenk, G.L. (1991) Serotonin influences the behavioral recovery of rats
following nucleus basalis lesions. Pharmacology, Biochemistry & Behavior, 38: 731-737.
Wenk, G.L., Casanova, M., Naidu, S., Kitt, C. A. & Moser, H. (1991) Altered neurochemical
markers in Rett syndrome. Neurology, 41: 1753-1756.
Olton, D.S., Markowska, A., Breckler, S.J., Wenk, G.L., Pang, K.C., Koliatsos, V. & Price, D.L.
(1991) Individual differences in aging: Behavioral and neural analyses. Biomedical and
Environmental Sciences, 4: 166-172.
(60)Olton, D.S., Markowska, A., Voytko, M.L., Givens, B., Gorman, L. & Wenk, G. Basal
forebrain cholinergic system: A functional analysis. In: T.C. Napier, P.W. Kalivas & I. Hanin,
(Eds.), The Basal Forebrain: Anatomy to Function, Plenum Press, New York, 1991, pp.
247-262.
Aigner, T.G., Mitchell, S.J., Aggleton, J.P., DeLong, M.R., Struble, R.G., Price, D.L., Wenk,
G.L., Pettigrew, K.D. & Mishkin, M. (1991) Transient impairment of recognition memory
following ibotenic acid lesions of the basal forebrain in macaques. Experimental Brain
Research, 86: 18-26.
Olton, D.S., Wenk, G.L. & Markowska, A.L. Basal forebrain, memory, and attention. In: R.
Richardson, (Ed.), Activation to Acquisition: Functional Aspects of the Basal Forebrain
Cholinergic System, Birkhauser, Boston, MA, 1991, pp. 247-262.
Wenk, G.L. The influence of neurotensin upon cholinergic function. In: L.L. Butcher & E.D.
Levin, (Eds.), Neurotransmitter Interactions and Cognitive Function, Birkhauser, Boston,
MA, 1992, pp. 196-206.
Naidu, S., Wong, D.F., Kitt, C., Wenk, G. & Moser, H.W. (1992) Positron emission tomography
in the Rett Syndrome: Clinical, biochemical and pathological correlates. Brain and
Development, 14: S75-S79.
Wenk, G.L., Harrington, C.A., Walker, L.C., Tucker, D.A. & Rance, N.E. (1992) Basal forebrain
neurons and memory: A biochemical, histological and behavioral study of differential
vulnerability to ibotenate and quisqualate. Behavioral Neuroscience, 106: 909-923.
Wenk, G.L. Dietary factors that influence the neural substrates of memory. In: R.L. Isaacson &
K. Jensen (Eds.), The Vulnerable Brain and Environmental Risks. Vol 1: Malnutrition and
Hazard Assessment, Plenum, New York, NY, 1992, pp. 67-75.
Stone, W.S., Wenk, G.L., Stone, S.M. & Gold, P.E. (1992) Glucose attenuation of paradoxical
sleep deficits in old rats. Behavioral and Neural Biology, 57: 79-86.
Wenk, G.L. Animal models of Alzheimer's disease. In: A.A. Boulton, G.B. Baker & R.F.
Wenk
12
Butterworth, (Eds.), Neuromethods 21: Animal Models of Neurological Disease. I., Humana
Press, Clifton, NJ, 1992, pp. 29-63.
Harrington, C.A. and Wenk, G.L. (1992) Differential vulnerability of basal forebrain cholinergic
and NADPH-diaphorase cells. Psychobiology, 20: 254-260.
(70)Davis, S., Markowska, A.L., Wenk, G.L. & Barnes, C.A. (1993) Chronic administration of
acetyl-l-carnitine: Behavioral, electrophysiological and neurochemical effects. Neurobiology
of Aging, 14: 107-115.
Wenk, G.L. Learning and memory: Psychopharmacology and aging. In: J.H. Byrne, L. Nadel,
H.L. Roediger, D.L. Schacter & R.F. Thompson, (Eds.), Encyclopedia of Learning and
Memory, Macmillian, New York, NY, 1993, pp. 5-7.
Cork, L.C., Walker, L., Wagster, M., Wenk, G.L., Struble, R., Bachevalier, J., Applegate, M. &
Price, D.L. (1993) Aged nonhuman primates as animal models of Alzheimer's Disease.
Brain Pathology, 24: 112-118.
Moyse, E., Szigethy, E., Beaudet, A., Danger, J.M., Vaudry, H., Wenk, G.L., Beaudet, A. &
Epelbaum, J. (1993) Short and long term effects of nucleus basalis magnocellularis lesions
on cortical levels of somatostatin and its receptors in the rat. Brain Research, 607: 154160.
Wenk, G. (1993) A Primate model of Alzheimer's Disease. Behavioral Brain Research, 117-122.
Wenk, G.L., O'Leary, M., Nemeroff, C.B., Bissette, G., Moser, H. & Naidu, S. (1993)
Neurochemical alterations in Rett syndrome. Developmental Brain Research, 74: 67-72.
Ricaurte, G.A., Markowska, A.L., Wenk, G.L., Hatzidimitriou, G., Wlos, J. & Olton, D.S. (1993)
MDMA, serotonin and memory. Journal of Pharmacology and Experimental Therapeutics,
266: 1097-1105.
Wenk, G. (1993) Age-related changes in monkey and rodent neurochemistry. Neurobiology of
Aging, 14: 689-690.
Wenk, G. (1994) David S. Olton: In Remembrance. Psychobiology, 22: 93-94.
Harrington, C.A., Mobley, S.L. & Wenk, G.L. (1994) Nitric oxide does not underlie the memory
deficits produced by ibotenate injections into the nucleus basalis. Behavioral Neuroscience,
108: 277-283.
(80)Wenk, G.L., Danysz, W. & Mobley, S.L. (1994) Investigations of neurotoxicity and
neuroprotection within the nucleus basalis of the rat. Brain Research, 655: 7-11.
Ragozzino, M.E., Wenk, G.L. & Gold, P.E. (1994) Glucose attenuates morphine-induced
Wenk
13
decrease in hippocampal acetylcholine output: an in vivo microdialysis study in rats. Brain
Research, 655: 77-82.
Wenk, G.L., Stoehr, J.D., Quintana, G., Mobley, S.L. & Wiley, R.G. (1994) Behavioral,
biochemical, histological and electrophysiological effects of 192 IgG-saporin injections into
the basal forebrain of rats. Journal of Neuroscience, 14: 5986-5995.
Wenk, G.L. (1994) The influence of psychotropic drugs upon intelligence. In: Encyclopedia of
Human Intelligence, Macmillan, New York, NY, pp. 362-368.
Wenk, G.L. (1995) Alterations in dopaminergic function in Rett Syndrome. Neuropediatrics, 26:
123-125.
Wenk, G.L., Rance, N.E. & Mobley, S.L. (1995) Effects of nucleus basalis lesions upon neurons
expressing neurokinin B and acetylcholine. Brain Research, 679: 8-14.
Wenk, G.L., Danysz, W., & Mobley, S.L. (1995) MK-801, memantine and amantadine show
potent neuroprotective activity against NMDA toxicity in the NBM - A dose response study.
European Journal of Pharmacology, 293: 267-270.
Stoehr, J.D. & Wenk, G.L. (1995) Effects of age and lesions of the nucleus basalis on
contextual fear conditioning. Psychobiology, 23: 173-177.
Wenk, G.L., Stoehr, J.D., Mobley, S.L., Gurney, J. & Morris, R.J. (1996) Age-related decrease
in vulnerability to excitatory amino acids in the nucleus basalis. Neurobiology of Aging, 17:
1-7.
Wenk, G.L. (1996) Neuroprotection and selective vulnerability of neurons within the nucleus
basalis magnocellularis. Behavioral Brain Research, 72: 17-24.
(90)Wenk, G.L. & Mobley, S.L. (1996) Choline acetyltransferase activity and vesamicol binding
in Rett Syndrome and in rats with nucleus basalis lesions. Neuroscience, 73: 79-84.
Wenk, G.L., Danysz, W., & Roice, D.D. (1996). The effects of mitochondrial failure upon
cholinergic and glutamatergic toxicity within the nucleus basalis. NeuroReport, 7: 14531456.
Robinson, J.K., Wenk, G.L, Wiley, R.G., Lappi, D.A., & Crawley, J.N. (1996)192-IgG-saporin
immunotoxin and ibotenic acid lesions of nucleus basalis and medial septum produce
comparable deficits on delayed nonmatching to position in rats. Psychobiology, 24: 179186.
Shen, J., Barnes, C.A., Wenk, G.L., & McNaughton, B.L. (1996) Differential effects of selective
immunotoxic lesions of medial septal cholinergic cells on spatial reference and working
memory. Behavioral Neuroscience, 110: 1181-1186.
Wenk
14
Wenk, G.L. (1996) Rett syndrome: Evidence for normal dopaminergic function.
Neuropediatrics, 27: 256-259.
Wenk, G.L. (1997) The nucleus basalis magnocellularis cholinergic system: 100 years of
progress. Neurobiology of Learning and Memory, 67: 85-95.
Wenk, G.L., Zajaczkowski, W., & Danysz, W. (1997) Neuroprotection of acetylcholinergic basal
forebrain neurons by memantine and neurokinin B. Behavioral Brain Research, 83: 129133.
Wenk, G.L. (1997) Mechanisms of cholinergic cell death in the basal forebrain: The role of
inflammation. Perspectives in Brain Aging Research, 2: 5-10.
McDonald, M.P., Wenk, G.L, & Crawley, J.N. (1997) Analysis of galanin and the galanin
antagonist, M40, on delayed non-matching to position performance in rats lesioned with the
cholinergic immunotoxin 192 IgG-saporin. Behavioral Neuroscience, 111:552-563.
Wenk, G.L. (1997) Rett syndrome: A review of the neurobiological changes that underlie
specific symptoms. Progress in Neurobiology, 51: 383-391.
(100)Danysz, W., Parson, C.G., Karcz-Kubicha, M., Lazarewicz, J. and Wenk G. (1997) Novel
systemically active antagonists of the glycine site of NMDA receptor-Behavioral
characterization. Pharmacology & Toxicology, 80:17-20.
Stoehr, J.D., Mobley, S.L., Roice, D.D., Brooks, R., Baker, L. Wiley, R.G. & Wenk, G.L. (1997)
The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in
the rat. Neurobiology of Learning and Memory, 67: 214-227.
Wenk, G.L. (1997) Behavioral Neuroscience: Learning and Memory Protocols. In: J.N. Crawley
& P. Skolnick, (Eds.) Current Protocols in Neuroscience, Johns Wiley & Sons, Inc., New
York, NY.
Wenk, G.L. (1997) Cholinergic neurotransmitter abnormalities in Rett Syndrome. European
Child & Adolescent Psychiatry, 6: 14-18.
Hauss-Wegrzyniak, B., Dobrzanski, P., Stoehr, J.D. & Wenk, G.L. (1998) Chronic
neuroinflammation in rats reproduces components of the neurobiology of Alzheimer’s
disease. Brain Research, 780: 294-303.
Wenk, G.L., Baker, L.M., Hauss-Wegrzyniak, B., Danysz, W. & Stoehr, J.D. (1998) Novel
glycineB antagonists show neuroprotective activity in vivo. Amino Acids, 14: 223-226.
Wenk, G.L., Baker, L.M., Stoehr, J.D., Hauss-Wegrzyniak, B. & Danysz, W. (1998)
Wenk
15
Neuroprotection by novel antagonists at the N-methyl-D-aspartate receptor channel and
glycineB sites. European Journal of Pharmacology, 347: 183-187.
McDonald, M.P., Willard, L.B., Wenk, G.L, & Crawley, J.N. (1998) Combination of a galanin
antagonist with a muscarinic agonist improves working memory in cholinergically lesioned
rats. Journal of Neuroscience, 18: 5078-5085.
Wenk, G.L. & Willard, L.B. (1998) The neural mechanisms underlying cholinergic cell death
within the basal forebrain. International Journal of Developmental Neuroscience, 16: 729735.
Hauss-Wegrzyniak, B., Willard, L.B, Pepeu, G., Del Soldato, P. & Wenk, G.L. (1999) Peripheral
administration of novel anti-inflammatories can attenuate the effects of chronic
inflammation within the CNS. Brain Research, 815:36-43.
(110)Willard, L.B., Hauss-Wegrzyniak, B. & Wenk, G.L. (1999) The pathological and
biochemical consequences of acute and chronic neuroinflammation within the basal
forebrain of rats. Neuroscience, 88: 193-200.
Pepeu, G. & Wenk, G.L. (1999) Brain inflammatory and neurotransmitter response to
lipopolysaccharide and interleukin-1-β. In: B. Vellas & J.L. Fitten, (Eds.) Research and
Practice in Alzheimer’s Disease and Other Dementias, pp 113-127.
Wenk, G.L. (1999) Functional neuroanatomy of learning and memory. In: D.S. Charney, E.J.
Nestler, & B.S. Bunney, (Eds.) Neurobiological Foundations of Mental Illness, First Edition,
Oxford University Press, New York, NY, pp. 679-684.
Voit, T., Abe, T., Antunes, N.L., Aso, K., Beck, M., Becker LE, Berthet F, Bourgeois B, Braddick
O, Cioni G, Cowan F, DiFazio MP, DiMauro S, Dodge N, Enders G, Forsting N, Frahm J,
Futagi Y, Gabreels-Festen A, Gartner J, Gillessen-Kaesbach G, Golden J, Greisen G,
Guichenai P, Hagberg B, Heinen F, Hohlfeld R, Holmes GL, Inoue Y, Iwamoto H, Jaeken J,
Kaufmann W, Kimura H, Kohyama J, Korinthenberg R, Kramer H, Kreth W, Krivit W, Logan
W, Lorenz B, Lou H, Martin JJ, Matshushima Y, Munnich A, Naidu S, Neubauer W, Oguni
H, Oka E, Osawa M, Panayiotopoulos CP, Partridge T, Raemaekers V, Rapin I, Reis A,
Rivkin M, Roll C, Rosenbaum T, Ross E, Rotteveel J, Schroder JM, Seitz R, Soul J,
Steinlein O, Stephani U, Tanaka J, Taylor G, Tome F, Topcu N, Tuxhorn I, Urlesberger B,
Wahn V, Wenk G, Wilichowski E, Wraith JE, Wynshaw-Boris A (1999) Rett syndrome.
Neuropediatrics 30: (6):277.
Wenk, G.L. & Hauss-Wegrzyniak, B. (1999) Altered cholinergic function in the basal forebrain of
girls with Rett Syndrome. Journal of Neuropediatrics, 30:125-129.
Hauss-Wegrzyniak, B., Vraniak, P. & Wenk, G. L. (1999) The effects of a novel NSAID upon
chronic neuroinflammation are age dependent. Neurobiology of Aging, 20: 305-313.
Wenk
16
Wenk, G.L., Hauss-Wegrzyniak, B. & Willard, L.B. (2000) Pathological and biochemical studies
of chronic neuroinflammation may lead to therapies for Alzheimer’s Disease. In: P.
Patterson, C. Kordon & Y. Christen, (Eds.) Research and Perspectives in Neurosciences:
Neuro-Immune Neurodegenerative and Psychiatric Disorders and Neural Injury, SpringerVerlag, Heidelberg, pp 73-77.
Wenk, G.L. (2000) Neurotoxicology: Learning and Memory. In: L. Costa, (Ed.) Current Protocols
in Toxicology, Johns Wiley & Sons, Inc., New York, NY, pp. 11.3.1-11.3.18.
Wenk, G.L. (2000) The immuno-lesioned animal as a model of transmitter dysfunction. In: D.F.
Emerich, R.L., Dean III & P.R. Sanberg, (Eds.) Central Nervous System Diseases: Innovative
Animal Models From Lab to Clinic, Humana Press, Totowa, NJ, pp. 81-92.
Wenk, G.L. (2000) Drugs and intelligence. In: A.E. Kazdin, (Ed.) Encyclopedia of Psychology,
American Psychological Association, Washington, DC & Oxford University Press, New
York, NY, Volume 3, pp. 101-104.
(120)Wenk, G.L., Quack, G., Moebius, H.-J. & Danysz, W. (2000) No interaction of memantine with
acetylcholinesterase inhibitors approved for clinical use. Life Sciences, 66: 1079-1084.
Hauss-Wegrzyniak, B., Vannucchi, M.G. & Wenk, G.L. (2000) Behavioral and ultrastructural
changes induced by chronic neuroinflammation in young rats. Brain Research, 859: 157166.
Hauss-Wegrzyniak, B., Vraniak, P., & Wenk, G.L. (2000) LPS-induced neuroinflammatory
effects do not recover with time. NeuroReport, 11: 1759-1763.
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cooper, N.R., Eikelenboom, P.,
Emmerling, M., Fiebich, B., Finch, C.E., Frautschy, S., Griffin, W.S.T., Hampel, H.,
Landreth, G., McGeer, P.L., Mrak, R., MacKenzie, I., O’Banion, K., Pachter, J., Pasinetti,
G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R.,
Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B.,
Wenk, G. & Wyss-Coray, A. (2000) Inflammation in Alzheimer’s disease. Neurobiology of
Aging, 21: 383-421.
Wenk, G.L., McGann, K., Fiorucci, S., Mencarelli, A., Hauss-Wegrzyniak, B., & Del Soldato, P.
(2000) Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain
cholinergic neurons. European Journal of Pharmacology, 402: 77-85.
Hauss-Wegrzyniak, B., Galons, J.P. & Wenk, G.L. (2000) Quantitative volumetric analysis of
brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation
with histology. Experimental Neurology, 165: 347-354.
Barnes, C.A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G.L. (2000) Chronic
Wenk
17
treatment of old rats with donepezil or galantamine: effects on memory, hippocampal
plasticity and nicotinic receptors. Neuroscience, 99: 17-23.
Willard, L. B., Hauss-Wegrzyniak, B., Danysz, W. & Wenk, G.L. (2000) The cytotoxicity of
chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be
attenuated by glutamatergic antagonism or cyclooxygenage-2 inhibition. Experimental
Brain Research, 134: 58-65.
Wenk, G.L. & Barnes, C.A. (2000) Regional changes in the hippocampal density of AMPA and
NMDA receptors across the lifespan of the rat. Brain Research, 885:1-5.
Wenk, G.L. & Hauss-Wegrzyniak, B. (2001) Animal models of chronic neuroinflammation as a
model of Alzheimer's Disease. In: S. Bondy & A. Campbell, (Eds.) Inflammatory Events in
Neurodegeneration. Prominent Press, Scottsdale, AZ, pp. 83-87.
(130)Perry, E., Lee, M., Martin-Ruiz, C., Court, J., Volsen, S., Merrit, J., Folly, E., Iversen, P.,
Bauman, M., Perry, R., & Wenk, G. (2001) Cholinergic Activities in Autism: Abnormalities in
the Cerebral Cortex and Basal Forebrain. American Journal of Psychiatry, 158: 1058-1066.
Woodruff-Pak, D.S., Vogel III, R.W, & Wenk, G.L. (2001) Galantamine: Effect on nicotinic
receptor binding, acetylcholinesterase inhibition, and learning. Proceedings of the National
Academy of Sciences, USA, 98: 2089-2094.
Gold, P.E., Cahill, L., & Wenk, G.L. (2002) Ginkgo biloba: A cognitive enhancer? Psychological
Science in the Public Interest, 3:2-11.
Jantzen, P.T., Connor, K.E., DiCarlo, G., Wenk, G.L., Wallace, J.L., Rojiani, A., Coppola, D.,
Morgan, D.G., & Gordon, M.N. (2002) Microglial activation and Aß deposit reduction
caused by a nitro-NSAID, NCX-2216 in APP+PS1 transgenic mice. Journal of
Neuroscience, 22: 2246-2254.
Hauss-Wegrzyniak, B., Lynch, M.A., Vraniak, P.D., & Wenk G.L. (2002) Chronic brain
inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant pathgranule cell synapses. Experimental Neurology, 176: 336-341.
Marriott, L.K., Hauss-Wegrzyniak, B., Benton, R.S., Vraniak, P.D. & Wenk, G.L. (2002) Longterm estrogen therapy worsens the behavioral and neuropathological consequences of
chronic brain inflammation. Behavioral Neuroscience, 116: 902-911.
Aldini, G., Carini, M., Orioli, M., Facino, R.M. & Wenk, G.L. (2002) Metabolic profile of NOflurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sciences, 71: 14871500.
Hauss-Wegrzyniak, B. & Wenk, G.L. (2002) Beta-amyloid deposition in the brains of rats
chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the
Wenk
18
vehicle. Neuroscience Letters, 322: 75-78.
Wrenn, C.C., Marriott, L., Kinney, J.W., Holmes, A., Wenk, G.L., & Crawley, J.L. (2002) Galanin
peptide levels in hippocampus and cortex of galanin overexpressing transgenic mice
evaluated for cognitive performance. Neuropeptides, 36:413-426.
Wenk, G.L., Rosi, S., McGann, K. & Hauss-Wegrzyniak, B. (2002) A nitric oxide-donating
flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in
the rat. European Journal of Pharmacology, 453: 319-324.
(140)Wenk, G.L. (2003) Neurotransmitters. In: L. Nadel (Ed.) Encyclopedia of Cognitive
Science, Nature Publishing Group, Macmillan Press, London, pp. 2414-2421.
Wenk, G.L. & Hauss-Wegrzyniak, B. (2003) Chronic intracerebral LPS as a model of
neuroinflammation. In: P.L. Wood, (Ed.) Neuroinflammation: Mechanisms and
Management, 2nd Ed., Humana Press, Totowa, NJ, pp. 137-150.
Wenk, G.L. (2003) Functional neuroanatomy of learning and memory. In: D.S. Charney, E.J.
Nestler, & B.S. Bunney, (Eds.) Neurobiology of Mental Illness, 2nd Ed., Oxford University
Press, New York, NY, pp. 807-812.
Woodruff-Pak, D.S., Vogel III, R.W. & Wenk, G.L. (2003) Mecamylamine interactions with
galantamine and donepezil: effect on learning, acetylcholinesterase, and nicotinic
acetylcholine receptors. Neuroscience, 117: 439-447.
Gold, P.E., Cahill, L., & Wenk, G.L. (2003) The lowdown on Ginkgo biloba. Scientific American,
April, 86-91.
Doody, R.S., Mintzer, J.E., Sano, M., Wenk, G.L. & Grossberg, G.T. (2003) Alzheimer’s
disease: Emerging non-cholinergic treatments. Geriatrics, (Suppl) 3-11.
Rosi, S., McGann, K., Hauss-Wegrzyniak, B. & Wenk, G.L. (2003) The influence of brain
inflammation upon neuronal adenosine A2B receptors. Journal of Neurochemistry, 86:220227.
Wenk, G.L., McGann, K., Hauss-Wegrzyniak, B. & Rosi, S. (2003) The toxicity of tumor
necrosis factor-α upon cholinergic neurons within the nucleus basalis and the role of
norepinephrine in the regulation of inflammation: implications for Alzheimer’s disease.
Neuroscience, 121: 719-729.
Wenk, G.L. (2003) Neuropathologic changes in Alzheimer¹s Disease. Journal of Clinical
Psychiatry, 64 (Suppl 9): 7-10.
Rogawski, M. & Wenk, G.L. (2003) The neuropharmacological basis for Memantine in the
Wenk
19
treatment of Alzheimer's disease. CNS Drug Reviews, 9: 275-308.
(150)Wenk, G.L. (2003) Inflammation in Alzheimer’s disease: its role and an opportunity for
therapy. Brain Aging: International Journal, 3:16-20.
Marriott, L.K. & Wenk, G.L. (2004) Neurobiological consequences of long term estrogen
therapy. Current Directions in Psychological Science, 13: 173-176.
Wenk, G.L., McGann-Gramling, K. & Hauss-Wegrzyniak, B. (2004) The presence of the
APPSWE mutation in mice does not increase the vulnerability of cholinergic basal forebrain
neurons to neuroinflammation. Neuroscience, 125: 769-776.
Wenk, G.L., McGann-Gramling, K., Hauss-Wegrzyniak, B., Ronchetti, D., Maucci, R., Rosi, S.,
Gasparini, L. & Ongini, E. (2004) Attenuation of chronic neuroinflammation by a nitric oxidereleasing derivative of the antioxidant ferulic acid. Journal of Neurochemistry, 89: 484-493.
Wrenn, C.C., Kinney, J.W., Marriott, L.K., Holmes, A., Harris, A.P., Saavedra, M.C., Starosta,
G., Innerfield, C.E., Jacoby, A.S., Shine, J., Iismaa, T.P., Wenk, G.L. & Crawley, J.N.
(2004) Learning and memory performance in mice lacking the GAL-R1 subtype of galanin
receptor. European Journal of Neuroscience, 19:1384-1396.
Wenk, G.L. (2004) The role of BDNF and dopamine dysfunction in autism, In: M.L. Bauman &
T.L. Kemper, (Eds.) The Neurobiology of Autism, 2nd Ed., The Johns Hopkins University
Press, Baltimore, MD, pp. 362-370.
Woodruff-Pak, D.S., Ewers, M., Shiotani, T., Watabe, S., Tanaka, M. & Wenk, G.L. (2004)
Nefiracetam and physostigmine: separate and combined effects on learning in older
rabbits. Neurobiology of Aging, 25: 807-816.
Rosi, S., Ramirez-Amaya, V., Hauss-Wegrzyniak, B. & Wenk, G.L. (2004) Chronic brain
inflammation leads to a decline in hippocampal NMDA R1 receptors. Journal of
Neuroinflammation, 1:12-18.
Gasparini, L., Ongini, E. & Wenk, G.L. (2004) Non-steroidal anti-inflammatory drugs (NSAIDS)
in Alzheimer’s disease: old and new mechanisms of action. Journal of Neurochemistry, 91:
521-536.
Mohmmad Abdul, H., Wenk, G.L., McGann-Gramling, K., Hauss-Wegrzyniak, B. & Butterfield,
D.A. (2004) APP and PS-1 mutations induce brain oxidative stress independent of dietary
cholesterol: implications for Alzheimer’s disease. Neuroscience Letters, 368: 148-150.
(160)Rosi, S., Ramirez-Amaya, V., Vazdarjanova, A., Worley, P.F., Barnes, C.A. & Wenk, G.L.
(2005) Neuroinflammation alters selective patterns of behaviorally induced Arc expression
in the hippocampus. Journal of Neuroscience, 25: 723-731.
Wenk
20
Daiello, L.A., Galvin, J.E. & Wenk, G.L. (2005) A case-based approach to management of
Alzheimer’s disease across the disease continuum. US Pharmacist, 30: (suppl. 2) 2-5.
Rosi, S., Pert, C.B., Ruff, M.R., McGann-Gramling, K. & Wenk, G.L. (2005) CCR5 chemokine
receptor antagonist DAPTA reduces microglia and astrocyte activation within the
hippocampus in a neuroinflammatory rat model of Alzheimer’s disease. Neuroscience, 134:
671-676. PMID: 15979806
Hasler, B.P., Cousins, J.C., Fridel, K.W., Wenk, G., & Bootzin, R.R. (2005). Effect of sleep
treatment on circadian rhythms in adolescents with a history of substance abuse. Sleep,
28: A64-A64.
Rosi, S., Vazdarjanova, A., Ramirez-Amaya, V., Worley, P.F., Barnes, C.A. & Wenk, G.L.
(2006) Memantine protects against LPS-induced neuroinflammation, restores behaviorallyinduced gene expression and spatial learning in the rat. Neuroscience, 142:1303-1315.
PMID: 16989956
Wenk, G.L. (2006) Neuropathologic changes in Alzheimer’s disease: Potential targets for
treatment. Journal of Clinical Psychiatry, 67: 3-7.
Wenk, G.L., Parson, C. & Danysz, W. (2006) Potential role of NMDA receptors as executors of
neurodegeneration resulting from diverse insults – focus on memantine. Behavioral
Pharmacology, 17: 411-424.
Danysz, W., Wenk, G.L., Banerjee, P. & Parsons, C. (2006) Preclinical basis for memantine
efficacy in Alzheimer's disease. Behavioral Pharmacology, 17: 538-540.
Marriott, L.K., McGann-Gramling, K.R., Hauss-Wegrzyniak, B., Sheldahl, L.C., Shapiro, R.A.,
Dorsa, D. & Wenk, G.L. (2007) Brain infusion of lipopolysaccharide increases uterine
growth as a function of estrogen replacement regimen: suppression of uterine ER by
constant, but not pulsed, estrogen replacement. Endocrinology, 148:232-240. PMID:
17023524
Wenk, G.L. (2007) Neurodegenerative diseases and memory – A treatment approach. , In: R.P.
Kesner & J.L. Martinez, (Eds.) Neurobiology of Learning and Memory, 2nd Ed., Elsevier,
519-539.
(180)Marchalant, Y., Rosi, S. & Wenk, G.L. (2007) Anti-inflammatory property of the
cannabinoid agonist WIN-55212-2 in a rodent model of Alzheimer’s disease. Neuroscience,
144:1516-1522.
Marriott, L.K., McGann-Gramling, K.R., Hauss-Wegrzyniak, B., Sheldahl, L.C., Shapiro, R.A.,
Dorsa, D.M. & Wenk, G.L. (2007) Estrogen replacement regimen and inflammatory
stressors in the brain differentially alter steroid receptors in the uterus and hypothalamus.
Endocrine, 32:317-328. PMID: 18247162
Wenk
21
Marchalant, Y., Brothers, H.M. & Wenk, G.L. (2008) Neuroinflammation in young and aged rats:
Influence of endocannabinoids and caffeine. Journal of Neuroimmunology, 197:168-170.
Hasler, B.P., Bootzin, R.R., Cousins, J.C., Fridel, K., & Wenk, G.L. (2008) Circadian
Phase in Sleep-Disturbed Adolescents with a History of Substance Abuse: A Pilot Study.
Behavioral Sleep Medicine, 6:55-73. PMID: 18412037
Marchalant, Y., Brothers, H.M. & Wenk, G.L. (2008) Inflammation and aging: can
endocannabinoids help? Biomedicine & Pharmacotherapy. 62:212-217. PMID: 18400455
Marchalant, Y., Cerbai, F., Brothers, H. & Wenk, G.L. (2008) Cannabinoid receptor stimulation
is anti-inflammatory and improves memory in old rats. Neurobiology of Aging, 29:18941901. PMID: 17561311
Wenk, G.L. (2008) Neuroanatomy of learning and memory. In: D.S. Charney, E.J. Nestler, &
B.S. Bunney, (Eds.) Neurobiology of Mental Illness, 3rd Ed., Oxford University Press, New
York, NY, p.920-931.
Wenk, G.L. & Marchalant, Y. (2009) Neuropharmacology. In: G.G. Berntson & J.T. Cacioppo,
(Eds.) Handbook of Neuroscience for the Behavioral Sciences, John Wiley & Sons, New
Jersey, p. 82-98.
Marchalant, Y., Brothers, H.M., Norman, G.J., Karolina, K., DeVries, C. & Wenk, G.L. (2009)
Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis.
Neurobiology of Disease, 34: 300-307. PMID: 19385063
Rosi, S., Ramirez-Amaya, V., Vazdarjanova, A., Esperanza, E., Larkin, P., Fike, J.R., Wenk,
G.L. & Barnes, C.A. (2009) Accuracy of hippocampal network activity is disrupted by
neuroinflammation: rescue by memantine. Brain, 132: 2464-2486. PMID: 19531533
(190)Marchalant, Y., Brothers, H.M. & Wenk, G.L. (2009) Cannabinoid agonist WIN-55,212-2
partially restores neurogenesis in the aged rat brain. Molecular Psychiatry, 14:1068-1071.
PMID: 19920834
Wenk, G.L. (2010) Your Brain on Food: How chemicals control your thoughts and feelings,
Oxford University Press, U.K.
Brothers, H.M., Marchalant, Y., & Wenk, G. L. (2010) Caffeine attenuates lipopolysaccharideinduced neuroinflammation. Neuroscience Letters, 480:97-100. PMID: 20541589
Norman, G.J., Morris, J.S., Karelina, K., Weil, Z.M., Zhang, N., Al-Abed, Y., Brothers, H.M.,
Wenk, G.L., Pavlov, V.A., Tracey, K.J., DeVries, A.C. (2011) Cardiopulmonary arrest and
resuscitation disrupts cholinergic anti-inflammatory processes: a role for cholinergic α7
nicotinic receptors. Journal of Neuroscience, 31: 3446-3452. PMID: 21368056
Wenk
22
Marchalant, Y., Baranger, K., Wenk, G.L., Khrestchatisky, M. & Rivera, S. (2012) Can the
benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and
memory during normal aging be useful in AD prevention? Journal of Neuroinflammation, 9:
10-13. PMID: 22248015
Bardou, I. DiPatrizio, N., Brothers, H.M., Kaercher, R.M., Baranger, K., Mitchem, M.R., Hopp,
S.C., Wenk, G.L. & Marchalant, Y. (2012) Pharmacological manipulation of cannabinoid
neurotransmission reduces neuroinflammation associated with normal aging. Health,
4:679-684. doi: 10.4236/health.2012.429107
Cerbai, F., Lana, D., Nosi, D., Petkova-Kirova, P., Zecchi, S., Brothers, H., Wenk, G. L. &
Giovannini, M.G. (2012) The neuron-astrocyte-microglia triad in normal brain aging and a
model of neuroinflammation in the rat hippocampus. PlosOne, 7(9):e45250. PMID:
23028880
Bardou, I. Brothers, H.M., Kaercher, R.M., Hopp, S.C. & Wenk, G.L. (2013) Differential effects
of duration and age upon the consequences of neuroinflammation in the hippocampus.
Neurobiology of Aging, 34:2293-2301. DOI:10.1016/j.neurobiolaging.2013.03.034
Brothers, H.M., Bardou, I., Hopp, S.C., Marchalant, Y., Kaercher, R.M., Turner, S.M., Mitchem
M.R., Kigerl K. & Wenk, G.L. (2013) Time-dependent compensatory responses to chronic
neuroinflammation in hippocampus and brainstem: the potential role of glutamate
neurotransmission. The Journal of Alzheimer's Disease & Parkinsonism, March 28, 3:110.
PMCID: PMC3939715; http://dx.doi.org/10.4172/2161-0460.1000110
Brothers, H.M., Bardou, I., Hopp, S.C., Kaercher, R.M., Wynne-Corona, A., Fenn, A.M.,
Godbout, JP & Wenk, G.L. (2013) Riluzole partially rescues age-associated, but not LPSinduced, loss of glutamate transporters and spatial memory impairment. Journal of
Neuroimmune Pharmacology, 8:1098-1105. PMID: 2013-05-25_0010 Impact factor: 4.6
(200)Bardou, I. Brothers, H.M., Kaercher, R.M., Hopp, S.C., Royer, S. & Wenk, G.L. (2014) Age
and duration of inflammatory environment differentially affect the neuroimmune response
and catecholaminergic neurons in the midbrain and brainstem. Neurobiology of Aging,
35:1065-1073. doi:10.1016/j.neurobiolaging.2013.11.006.
Hopp, S.C., Royer, S., Brothers, H.M., Kaercher, R.M., D’Angelo , H., Bardou, I. & Wenk, G.L.
(2014) Age-associated alterations in the time-dependent profile of pro- and antiinflammatory proteins within the hippocampus in response to acute exposure to interleukin1β. Journal of Neuroimmunology, 267:86-91 DOI: 10.1016/j.jneuroim.2013.12.010
Duarte, J.M.N., Schuck, P.F., Wenk, G.L. & Ferreira, G.C. (2014) Metabolic disturbances in
diseases with neurological involvement. Aging & Disease, 5: April. DOI:10.14336/AD.
Wenk
23
CONFERENCE PRESENTATIONS AND ABSTRACTS:
Wenk, G.L. and Stemmer, K.L. Neurotoxicity of aluminum exposure via the diet in rats.
Society for Neuroscience, Atlanta, November, 1979.
Wenk, G.L. The neurotoxic effects of aluminum exposure upon brain dopamine,
norepinephrine, and epinephrine levels, as determined by high pressure liquid chromatography
with an electrochemical detector. First International Symposium on the Neurochemical and
Clinical Applications of LCEC., Indianapolis, May, 1980.
Wenk, G.L. and Stemmer, K.L. Essential, dietary metal imbalance and aluminum
intoxication: interaction with the catecholamine systems. Society for Neuroscience, Cincinnati,
November, 1980.
Wenk, G.L. and Stemmer, K.L. The influence of dietary aluminum upon regional trace
metals, catecholamines, and enzyme activity in the rat. Society of Toxicology, San Diego,
March, 1981.
Wenk, G.L. and Stemmer, K.L. Activity of the enzymes dopamine-beta- hydroxylase and
phenylethanolamine-N-methyltransferase in discrete brain regions of the rat following aluminum
ingestion. Society for Neuroscience, Los Angeles, October, 1981.
Stemmer, K.L. and Wenk, G.L. Interactions between aluminum and the essential trace
metals in brain and testes. Symposium on Clinical Trials Bases on the Hypothesis of Aluminum
Toxicity. Toronto, November, 1981.
Wenk, G.L. and Suzuki, K. The effect of copper supplementation on the concentration of
copper and the activity of dopamine-beta-hydroxylase in the brain of the brindled mouse.
Society for Neuroscience. Minneapolis, October, 1982.
Wenk, G.L., Hepler, D. and Olton, D. The influence of behavior on (3H)-choline uptake
into acetylcholinergic neurons of the nucleus basalis of Meynert and the medial septal
area. Society for Neuroscience, Boston, November, 1983.
Hepler, D., Wenk, G.L., Olton, D., Lehmann, J. and Coyle, J. Lesions in nucleus basalis of
Meynert and medial septal area of rats produce similar impairments in three behavioral
tasks. Society for Neuroscience, Boston, November, 1983.
Wenk, G.L., Lui, J. & Stemmer, K. Interactions of aluminum and zinc related to certain
brain and endocrine functions. Proceedings of the International Conference on Heavy Metals in
the Environment, World Health Organization and Commission of the European Communities,
Heidelburg, August, 1983.
Olton, D.S., Hepler, D., Wenk, G.L., Lehmann, J. and Coyle, J. Lesions of the nucleus
basalis magnocellularis and medial septal area in rats produce similar memory
Wenk
24
impairments. Proceedings of the Third Meeting of the International Study Group on the
Treatment of Memory Disorders Associated with Aging. Zurich, January, 1984.
Wenk, G.L. Pharmacological regulation of the substantia innominata neocortical cholinergic
pathway. New York Academy of Sciences, New York, June, 1984.
Hepler, D., Wenk, G.L., Olton, D. and Coyle, J. Lesions in nucleus basalis magnocellularis
and medial septal area of rats produce similar memory impairments in appetitive and
non-appetitive behavioral tasks. New York Academy of Sciences, New York, June, 1984.
Wenk, G.L. and Olton, D. Radial maze performance in rats with basal forebrain lesions can
be improved with drug therapy. Society for Neuroscience, Anaheim, October, 1984.
Hepler, D., Olton, D., Wenk, G.L. and Coyle, J. Lesions in the nucleus basalis
magnocellularis and medial septal area of rat produce qualitatively similar memory impairments
in a T-maze task. Society for Neuroscience, Anaheim, October, 1984.
Wenk, G.L. Pharmacological regulation of the substantia innominata-neocortical
cholinergic pathway. Society for Neuroscience, Anaheim, October, 1984.
Aigner, T., Mitchell, S., Martin, S., Aggleton, J., DeLong, M., Struble, R., Wenk, G.L., Price,
D. and Mishkin, M. Recognition deficit in monkeys following neurotoxic lesions of the basal
forebrain. Society for Neuroscience, Anaheim, October, 1984.
Olton, D.S. and Wenk G.L. Radial maze acquisition in rats with basal forebrain lesions can
be accelerated with drug therapy. Conference on Alzheimer's Disease and Dementia: Prospects
and Perspective, Detroit, November, 1984.
Olton, D., Wenk, G., and Hughey, D. Radial maze acquisition in rats with basal forebrain
lesions can be accelerated with drug therapy. Fifth Annual Chemical Defense Bioscience
Review, Applied Physics Laboratory, Johns Hopkins University, Columbia, May, 1985.
Wenk, G. The basal forebrain cholinergic system and memory. Proceedings of the IVth
World Congress of Biological Psychiatry, Philadelphia, 1985.
Wenk, G., Engisch, K., Aigner, T., Mitchell, S., Struble, R., Price, D., Mishkin, M. and Olton,
D. Serotonin type 2 receptor binding in monkey and rodent brains following basal forebrain
lesions with ibotenic acid. Society for Neuroscience, Dallas, October, 1985.
Hughey, D.J., Wenk, G.L. and Olton, D.S. Lesions of the nucleus basalis magnocellularis
impair maze learning in rats. Society for Neuroscience, Dallas, October, 1985.
Meck, W.H., Church, R.M., Wenk, G.L. and Olton, D.S. Ibotenic acid lesions of the medial
septal area and nucleus basalis magnocellularis cause differential impairments in temporal
memory. Society for Neuroscience, Dallas, October, 1985.
Wenk
25
Brown, M., Hohmann, C.F., Lowenstein, P.R., Meck, W., Wenk, G.L. and Coyle,
J.T. Age-related re-appearance of partial basal forebrain cholinergic deficits. Society for
Neuroscience, Dallas, October, 1985.
Raffaele, K., Hughey, D., Wenk, G., Olton, D., Modrow, H., Mayes, M. and McDonough,
J. Long term behavioral changes in rats following acute organophosphate exposure. Society for
Toxicology, New Orleans, March, 1986.
Sweeney, J., Wenk, G.L. and Olton, D.S. Behavioral effects of an irreversible choline
acetyltransferase inhibitor. Society for Toxicology, New Orleans, March, 1986.
D'Amato, R.J., Whitehouse, P.J., Wenk, G.L., Zweig, R.M., Mayeux, R., Price, D.L. and
Snyder, S.H. Monoaminergic systems in Alzheimer's and Parkinson's diseases. American
Neurological Association, San Antonio, 1986.
Wenk, G.L. and Engisch, K.L. Basal forebrain lesions with ibotenic acid increase
serotonin-2 binding in rat and monkey cortex. European Society for Neurochemistry, Prague,
September,1986.
Wenk, G.L., Olton, D.S., Hughey, D., and Engisch, K. Animal models of cholinergic
dysfunction related to aging and senile dementia. World Federation of Neurology Cerebral
Metabolism in Aging and Neurological Disorders. Baden/Vienna, August, 1986.
Wenk, G.L., Hughey, D.J., Cribbs, B., U'Prichard, T., and Olton, D.S. Behavioral and
biochemical effects of norepinephrine, dopamine, and serotonin depletion within the frontal
neocortex of the rat. Society for Neuroscience, Washington, November, 1986.
Hughey, D.J., Wenk, G.L., and Olton, D.S. Spontaneous, cholinergic-dependent,
behavioral recovery following basal forebrain lesions. Society for Neuroscience, Washington,
November, 1986.
Meck, W.H., Church, R.M., Wenk, G.L., and Olton, D.S. Simultaneous temporal processing
and the basal forebrain cholinergic system. Society for Neuroscience, Washington, November,
1986.
Wenk, G.L. Animal models of Alzheimer's disease. First International Symposium of
Biological Psychiatry, Belo Horizonte, November, 1986.
Olton, D., Wenk, G., and Pontecorvo, M. Cognitive enhancers: Research therapies and
results. C.I.N.P., San Juan, December, 1986.
Wenk, G.L. Neural plasticity in Alzheimer's disease. 20th Annual Winter Conference on
Brain Research, Vail, January, 1987.
Pontecorvo, M.J., Olton, D.S., White, M.F., Conti, L.H., and Wenk, G.L. Norepinephrine
Wenk
26
depletion by DSP4 does not prevent long term behavioral recovery following basal forebrain
lesions. Federation of American Societies for Experimental Biology, Washington, April, 1987.
Wenk, G.L. Behavioral effects of age-related degeneration in the cholinergic and
serotonergic neural systems. International Symposium on New Trends in Aging Research.
Italian Study Group on Brain Aging. Sirmione, April, 1987.
Wenk, G.L. and Olton, D.S. Animal models of Alzheimer's disease: Cholinergic and
serotonergic components of the dementia. Structural-Functional Properties of the Basal
Forebrain Cholinergic System, ESN-IBRO Satellite Symposium, Leipzig, August, 1987.
Wenk, G.L., Cork, L., Struble, R., Pierce, D., and Price, D. Age-related changes in primate
neurochemistry. Society for Neuroscience, New Orleans, November, 1987.
Hedreen, J., Wenk, G.L., and Battleman, D.S. Neurochemical changes in the cortex of
Huntington's disease patients: Possible basis for affective disorder. Society for Neuroscience,
New Orleans, November, 1987.
Atack, J.R., Wenk, G.L., Wagster, M.V., Kellar, K.J., Whitehouse, P.J., and Rapoport, S.I.
Bilateral changes in cortical cholinergic receptors following unilateral lesions of the rat nucleus
basalis: An autoradiographic study. Society for Neuroscience, New Orleans, November, 1987.
Szigethy, E., Wenk, G.L., Epelbaum, J., and Beaudet, A. Neurotensin binding in rat
nucleus basalis: effects of local ibotenic acid injections. Society for Neuroscience, New Orleans,
November, 1987.
Szigethy, E., Wenk, G.L., and Beaudet, A. Neurotensin receptors on cholinergic cells in the
forebrain. Winter Neuropeptide Conference, Breckenridge, January, 1988.
Olton, D.S. and Wenk, G.L. Animal models to investigate the role of NMDA receptors in
learning and memory. Excitatory Amino Acids '88, Manhaus, April, 1988.
Wenk, G.L. Experimental behavior strategies to study altered cognitive functions.
"Psychopharmacology: An Up To Date", The Association for the Advancement of
Neurosciences, Rome, September, 1988.
Wenk, G.L., Markowska, A., and Olton, D.S. Differential effects of quisqualate or ibotenate
injected into nucleus basalis magnocellularis (NBM) on behavior and neurochemistry. Society
for Neuroscience, Toronto, November, 1988.
Chachich, M., Spangler, E., Smith, K., Wenk, G., and Ingram, D. Effects of noradrenergic
depletion and cholinergic antagonism on complex maze performance in young F-344 rats.
Society for Neuroscience, Toronto, November, 1988.
Olton, D.S., Wenk, G.L., and Markowska, A. Cognitive functions of the basal forebrain.
Wenk
27
Society for Neuroscience, Toronto, November, 1988.
Price, D.L., Koo, E.H., Wagster, M.V., Walker, L.C., Wenk, G.L., Applegate, M.D., and
Cork, L.C. Behavioral, cellular, and molecular biological studies of aged nonhuman primates.
Proceedings of the Fifth Meeting of the International Study Group on the Treatment of Memory
Disorders Associated with Aging. Zurich, January, 1989.
Wenk, G.L. and Grey, C. Age-related changes in NMDA and GABA receptors in the rat
brain. American Society for Neurochemistry, Chicago, March, 1989.
Battleman, D.S., Wagster, M.V., Wenk, G.L., Hadfield, M.G., Price, D.L., and Hedreen, J.C.
Studies of neuroreceptor binding in neocortex in Huntington's disease. American Academy of
Neurology, Chicago, April,1989.
Wenk, G.L. Animal Models of neurodegenerative diseases: are they accurate and useful?
Recovery from Brain Damage: Behavioral and Neurochemical Approaches, Satellite
Symposium of the XXXI International Congress of Physiological Sciences (IUPS), Warsaw,
July, 1989.
Wenk, G.L., Naidu, S., and Moser, H. Altered neurochemical markers in Rett syndrome.
Child Neurology Society, San Antonio, October, 1989.
Markowska, A.L., Wenk, G.L., and Olton, D.S. Can serotonergic depletion influence
behavior following NBM lesions? Society for Neuroscience, Phoenix, October, 1989.
Wenk, G.L. Cysteine protects basal forebrain cholinergic neurons from ibotenic, but not
quisqualic, acid. Society for Neuroscience, Phoenix, October, 1989.
Wenk, G.L. Age-related memory loss: The role of acetylcholine and glutamate.
Neuroscience Winter Conference, St. Maartin, Netherlands Antilles, February, 1990.
Olton, D., Markowska, A., Wenk, G., Voytko, M.L., and Givens, B. Cognitive functions of
the basal forebrain. Basal Forebrain Conference, Chicago, May, 1990.
Voytko, M.L., Olton, D.S., Richardson, R.T., Wenk, G.L., and Price, D.L. Lack of memory
impairments following basal forebrain lesions in monkeys. Society for Neuroscience, St. Louis,
October, 1990.
Gorman, L.K., Olton, D.S., Plano, S., and Wenk, G.L. Pharmacological studies of
acetylcholine release by microdialysis in the freely moving rat. Society for Neuroscience, St.
Louis, October, 1990.
Wenk, G.L, Markowska, A.L, Gorman, L., Koliatsos, V.E., Price, D.L., and Olton, D.S.
Relationship of age-related behavioral deficits to neurochemical markers. Society for
Neuroscience, St. Louis, October, 1990.
Wenk
28
Wenk, G.L. The interaction of acetylcholine with neurotensin. 15th Annual, Winter
Conference on the Neurobiology of Learning and Memory, Park City, January, 1991.
Harrington, C.A. and Wenk, G.L. Behavioral consequences of the differential effects of
excitotoxic lesions in the nucleus basalis magnocellularis. Society for Neuroscience, New
Orleans, November, 1991.
Wenk, G.L., Harrington, C.A., and Gold, P.E. Control of the basal forebrain cholinergic
system: A microdialysis study. Society for Neuroscience, New Orleans, November, 1991.
Wilson, L.A., Warren, S.G., Amend, D.L., Nadel, L., and Wenk, G. Early experience alters
glucocorticoid receptor concentrations in the hippocampus. Society for Neuroscience, New
Orleans, November, 1991.
Chavoix, C., Aigner, T., Ogura, H., Wenk, G., Mishkin, M. Effets de substances
cholinergique et noradrenergiques sur la memoire de reconnaissance visuelle du singe rhesus
apres lesion bilaterale du systeme cholinergique du telencephale ventral. 1er Collogue de la
Societes des Neurosciences, Strasbourg, May 1992.
Bissette, G., Nemeroff, C.B., Naidu, S., Moser, H., and Wenk, G. Neuropeptide alterations
in Rett's syndrome. Society of Biological Psychiatry, August, 1993.
Davis, S., Wenk, G.L., Sage, A., Barnes, C.A., and McNaughton, B.L. The role of
noradrenergic input in the generation of short-term synaptic plasticity in the dentate gyrus.
Society for Neuroscience, Anaheim, October, 1992.
Wenk, G.L. Recent developments in animal models of Alzheimer's disease. Invited
Speaker. Western Psychological Association and Rocky Mountain Psychological Association,
Phoenix, April, 1993.
Hohmann, C.F., Kinsman, S.L., Moran, T.H., Wenk, G., Gibson, W., Ladenheim, B.N.,
Plano, S. and Oster-Granite, M.L. Effects of gender on choline acetyltransferase, somatostatin
and swim maze performance in mice transgenic for somatostatin and controls. Society for
Neuroscience, Washington, D.C., November, 1993.
Harrington, C.A., Mobley, S., and Wenk, G.L. Nitric oxide in basal forebrain neural
degeneration. Society for Neuroscience, Washington, D.C., November, 1993.
Ragozzino, M.E., Wenk, G.L., and Gold, P.E. Glucose attenuates morphine-induced
decreases in hippocampal acetylcholine output. Society for Neuroscience, Washington, D.C.,
November, 1993.
Wenk, G.L., Stoehr, J.D., Rance, N., and Mobley, S.L. Nucleus basalis: Age-increased
vulnerability to excitatory amino acids. Society for Neuroscience, Miami, November, 1994.
Wenk
29
Stoehr, J.D., Markus, E.J., Nadel, L., and Wenk, G.L. Effects of post-training
intrahippocampal and amygdaloid injections of scopolamine on contextual and cued-fear
conditioning. Society for Neuroscience, Miami, November, 1994.
Robinson, J.K., Wiley, R.G., Lappi, D.A., Wenk, G.L., and Crawley, J.N. Comparison of 192
IgG-saporin immunotoxin versus ibotenic acid lesions of nucleus basalis and medial septum:
comparable deficits in delayed nonmatching-to-sample (DNMTS) performance in rats. Society
for Neuroscience, Miami, November, 1994.
Wenk, G.L., Neurochemical and Psychopharmacological Approaches to Cognitive
Enhancers. International Society for Neurochemistry Satellite Symposium, Kyoto, Japan, July,
1995.
Wenk, G.L., The basal forebrain and memory: the influence of drugs and aging. Second
International Congress, Polish Neuroscience Society, Polish Academy of Sciences, Kracow,
September, 1995.
Danysz, W., Zajaczkowski, W., Misztal, M., and Wenk, G., The role of the glutamatergic
system in learning and memory- Behavioral studies. Second International Congress, Polish
Neuroscience Society, Polish Academy of Sciences, Kracow, September, 1995.
Wenk, G.L., Danysz, W., Chawla, M.K., and Rance, N.E., Neuroprotection from NMDA
within the nucleus basalis magnocellularis. Society for Neuroscience, San Diego, November,
1995.
Stoehr, J.D. and Wenk, G.L., The effects of basal forebrain lesions on expectancy in the
rat. Society for Neuroscience, San Diego, November, 1995.
Chawla, M.K., Gutierrez, G.M., Wenk, G.L., and Rance, N.E., Choline acetyltransferase
and neurokinin B mRNAs are colocalized in neurons of the human magnocellular basal
forebrain. Society for Neuroscience, San Diego, November, 1995.
Wenk, G.L., IgG 192-saporin: A novel immunotoxin: Redefining the role of cholinergic
neurons in the brain. 29th Winter Conference on Brain Research, Snowmass Village, CO,
January, 1996.
Wenk, G.L., Cholinergic neurotransmitter abnormalities in Rett Syndrome. World Congress
on Rett Syndrome, Göteborg, Sweden, August, 1996.
McDonald, M.P., Wenk, G.L., and Crawley, J.N., The actions of galanin and M40 on
delayed non-matching to position in 192 IgG-saporin-lesioned rats. Society for Neuroscience,
Washington, D.C., November, 1996.
Wenk, G.L, Roice, D. and Baker, L.M., A novel animal model of Alzheimer’s Disease:
Wenk
30
Cholinergic cytotoxicity induced by inflammatory cytokines. Society for Neuroscience,
Washington, D.C., November, 1996.
Wenk, G.L., Baker, L.M., Wegrzyniak, B., Stoehr, J.D. and Danysz, W., Novel glycine B
antagonists show neuroprotective activity in vivo. 5th International Congress on Amino Acids,
Cahlkidiki, Greece, August, 1997.
McDonald, M.P., Miller, K.M., Goldstein, G., Wenk, G.L. and Crawley, J.N. Coadministration of galanin antagonist M40 with a cholinesterase inhibitor or a muscarinic M1
agonist on delayed non-matching to position choice accuracy in 192 IgG-saporin-lesioned rats.
Society for Neuroscience, New Orleans, October, 1997.
Baker, L.M., Hauss-Wegrzyniak, B., Stoehr, J.D. and Wenk, G.L. Neuroinflammation
destroys basal forebrain cholinergic neurons in a time dependent manner. Society for
Neuroscience, New Orleans, October, 1997.
Stoehr, J.D., Baker, L.M., Wegrzyniak, B., Danysz, W. and Wenk, G.L. Novel glycine b
antagonists show neuroprotective activity in vivo. Society for Neuroscience, New Orleans,
October, 1997.
Hauss-Wegrzyniak, B., Baker, L.M., Stoehr, J.D. and Wenk, G.L. Chronic
neuroinflammation induces selected neuronal cell death in rats. Society for Neuroscience, New
Orleans, October, 1997.
Pepeu, G., Casamenti, F., Prosperi, C., Scali, C., Giovannelli, L., Hauss-Wegrzyniak, B.,
Baker, L.M., and Wenk, G.L. Inflammatory and neurotransmitter response to
lipopolysaccharide (LPS) and interleukin-1 (IL-1) intracerebral injections. The Fifth
International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva,
Switzerland, April, 1998.
Wenk, G.L., Hauss-Wegrzyniak, B., Willard, L.B., and Danysz, W. A novel animal model of
Alzheimer’s Disease: Chronic neuroinflammation of transgenic rats that overexpress human amyloid. The Sixth International Conference on Alzheimer’s Disease, Amsterdam, The
Netherlands, July, 1998.
Baker, L.M., Hauss-Wegrzyniak, B., and Wenk, G.L. The effect of a novel NO-NSAID on
chronic neuroinflammation. Fifth International Congress of the International Society of
Neuroimmunology, Montreal, Canada, August, 1998.
Wenk, G.L., Hauss-Wegrzyniak, B., and Willard, L.B. Studies of neuroprotection from the
pathological and biochemical effects of chronic neuroinflammation in rats – potential therapies
for Alzheimer’s Disease. Colloques Medecine et Recherche, Ninth Series, Neuro-Immune
Interactions in Neurodegenerative Disease, Mental Illness and Neural Injury, Paris, October,
1998.
Wenk
31
McDonald, M.P., Araujol, K., Willard, L.B., Wenk, G.L. and Crawley, J.N. Effects of sitespecific injections of galanin antagonist M40 with a muscarinic M1 agonist on delayed nonmatching to position choice accuracy in 192 IgG-saporin-lesioned rats. Society for
Neuroscience, Los Angeles, November, 1998.
Willard, L. B., Hauss-Wegrzyniak, B. and Wenk, G.L. Novel neuroprotective approaches for
the treatment of Alzheimer’s Disease. Society for Neuroscience, Los Angeles, November, 1998.
Sutherland, G.R., Sutherland, V.L., Tucker, V.A., Wenk, G., Lynch, R.M., and Yool, A.J.
Characterization of glucose sensing neurons of the hypothalamus. Society for Neuroscience,
Los Angeles, November, 1998.
Hauss-Wegrzyniak, B. and Wenk, G.L. Prevention of chronic neuroinflammation by NOreleasing flurbiprofen in a new animal model of Alzheimer’s disesase. 4th World Congress on
Inflammation, Paris, June, 1999.
Hauss-Wegrzyniak, B., Galons, J.P., and Wenk, G.L. Chronic neuroinflammation
reproduces the temporal lobe atrophy seen in Alzheimer’s disease: A MRI study in young rats.
Society for Neuroscience, Miami, October, 1999
Barnes, C.A. and Wenk, G.L. Comparison of chronic treatment with galantamine or
donepezil in old rats: memory, hippocampal plasticity and nicotinic receptors. Sixth International
Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April, 2000
Wenk, G.L., Mencarelli, A., Hauss-Wegrzyniak, B., Del Soldato, P. and Fiorucci, S. Two
novel and safe cyclooxygenase inhibitors can prevent the neurodegeneration of basal forebrain
acetylcholinergic neurons. 11th International Conference on Advances in Prostaglandin and
Leukotriene Research: Basic Science and New Clinical Applications. Florence, June, 2000.
Wenk, G.L., Fiorucci, S., Hauss-Wegrzyniak, B., Danysz, W., and Del Soldato, P., An
investigation of mechanisms to prevent the cytotoxicity of chronic neuroinflammation upon basal
forebrain cholinergic neurons in young rats. Seventh International Conference on Alzheimer’s
Disease and Related Disorders, Washington, D.C, July, 2000.
Woodruff-Pak, D.S., Vogel, R.W. and Wenk,G.L. Acetylcholinesterase inhibition, learning,
and nicotinic receptors. Seventh International Conference on Alzheimer’s Disease and Related
Disorders, Washington, D.C, July, 2000.
Danysz, W., Moebius, H.-J., Parsons, C.G., Quack, G., Wenk, G.L. and Stoeffler, A.
Memantine provides neuroprotection in animal models at therapeutically relevant doses.
Seventh International Conference on Alzheimer’s Disease and Related Disorders, Washington,
D.C, July, 2000.
Parsons, C.G., Danysz, W., Moebius, H.-J., Quack, G., Stoeffler, A. and Wenk, G.L.
Wenk
32
Memantine restores impaired synaptic plasticity by reducing synaptic noise. Seventh
International Conference on Alzheimer’s Disease and Related Disorders, Washington, D.C,
July, 2000.
Hauss-Wegrzyniak, B., Vraniak, P.D. and Wenk, G.L. LPS-induced neuroinflammatory
effects do not recover with time. Neuroinflammation in Alzheimer’s Disease, Washington, D.C,
July, 2000.
Wenk, G.L. and Danysz, W. NMDA receptors as a target for neuroprotective treatment in
neurodegenerative dementia and the role of inflammation. 6th European Congress of
Pharmaceutical Sciences, Budapest, September, 2000.
Wenk, G.L., Mencarelli, A., Hauss-Wegrzyniak, B., Del Soldato, P. and Fiorucci, S.
Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic
neurons. Society for Neuroscience, New Orleans, November, 2000.
Woodruff-Pak, D.S., Vogel, R.W. III and Wenk G.L. Acetylcholinesterase inhibition,
learning and nicotinic receptors. Society for Neuroscience, New Orleans, November, 2000.
Ewers, M., Vogel, R.W. III, Wenk G.L. and Woodruff-Pak, D.S. Physostigmine ameliorates
impaired eyeblink classical conditioning in older rabbits. Society for Neuroscience, New
Orleans, November, 2000.
Hauss-Wegrzyniak, B.A., Galons, J.P. and Wenk, G.L., Stereological analysis of
hippocampal and entorhinal cortex neurons in a rat model of chronic brain inflammation.
Society for Neuroscience, New Orleans, November, 2000.
Wenk, G.L. and Hauss-Wegrzyniak, B., Chronic neuroinflammation: its role in
neurodegeneration and Alzheimer’s Disease. Banff Inflammation Workshop 2001, Banff,
Alberta, February, 2001.
Wenk, G.L. Cognition enhancement and neuroprotection. Session Chair and Organizer,
Winter Conference on Neural Plasticity. 13th Annual Meeting. Antigua, February, 2001.
Marriott, L.K., Hauss-Wegrzyniak, B., Benton, R.S., Vraniak, P.D. and G.L. Wenk. The role
of estrogen and chronic brain inflammation in Alzheimer's Disease. Society for Behavioral
Neuroendocrinology. Scottsdale, AZ, June, 2001.
Wenk, G.L. and Hauss-Wegrzyniak, B., NMDA receptors and cyclooxygenase as targets
for neuroprotection from the cytotoxicity of inflammatory proteins. 7th International Congress on
Amino Acids and Proteins, Vienna, August 2001.
Woodruff-Pak D. S., Ewers M., Vogel R. W., Shiotani T., Watabe S., Tanaka M. and Wenk
G. L., Nefiracetam enhances the effect of physostigmine (an allosteric potentiating ligand) on a
test sensitive to Alzheimer’s Disease. 5th International Conference on Progress in Alzheimer's
Wenk
33
Disease and Parkinson's Disease, Kyoto, 2001
Hauss-Wegrzyniak, B., Lynch, M. and Wenk, G.L. The role of chronic neuroinflammation
during long-term potentiation of synaptic transmission in the rat hippocampus. 5th World
Congress on Inflammation, Edinburgh, September, 2001.
Wenk, G.L. and Hauss-Wegrzyniak, B., Chronic neuroinflammation as an animal model of
Alzheimer’s Disease. Alzheimer’s Disease International, 17th International Conference. New
Zealand, October, 2001.
Marriott, L.K., Hauss-Wegrzyniak, B.A., Benton, R.S., Vraniak, P.D. and Wenk, G.L.,
Estrogen alters the behavioral and neuropathological consequences of chronic brain
inflammation. Society for Neuroscience, San Diego, November, 2001.
Wenk, G.L., Vraniak, P.D. and Hauss-Wegrzyniak, B.A., Neuroinflammation: long term
changes upon behavior and pathology. Society for Neuroscience, San Diego, November, 2001.
Hauss-Wegrzyniak, B.A., Lynch, M.A., Vraniak, P.D. and Wenk, G.L., The role of chronic
neuroinflammation during long-term potentiation of synaptic transmission in the rat
hippocampus. Society for Neuroscience, San Diego, November, 2001.
Watabe, S., Ewers, M., Vogel, R.W., Shiotani, T., Tanaka, M., Wenk, G.L. and WoodruffPak, D.S., Low doses of physostigmine potentiate the effect of nefiracetam on learning. Society
for Neuroscience, San Diego, November, 2001.
Wenk, G.L. and Barnes, C.A., Effects of chronic treatment with cognitive enhancing drugs
on nicotine receptor pharmacology. American College of Neuropsychopharmacology, Waikoloa,
Hawaii, December, 2001.
Galons, J.P., Chen, K., Stevenson, G., Hauss-Wegrzyniak, B., Valla, J., Wenk, G.L.,
Alexander, G.E.,Trouard, T. and Reiman, E.M. Detecting an experimentally induced reduction in
mouse brain volume using sequential high-resolution MRI’s and iterative PCA method. Arizona
Alzheimer’s Disease Research Council, January, 2002.
Chen, K., Reiman, E.M., He, T., Hauss-Wegrzyniak, B., Galons, J.P., Stevenson, G.,
Valla, J., Trouard, T.P., Wenk, G.L. and Alexander, G.E. Evaluation of an iterative principal
component analysis for detecting whole brain volume change in small animal magnetic
resonance imaging. Arizona Alzheimer’s Disease Research Council, Neurobiology of Aging
23(1):S353-S353, January, 2002.
Wenk, G.L., Neuroinflammation in a double transgenic mouse model of Alzheimer's
disease. Winter Conference on Neural Plasticity. 14th Annual Meeting. Moorea, February, 2002.
Danysz, W., Moebius, H., Parsons, C., Quack, G., Wenk, G. and Stoeffler, A. Memantine
provides neuroprotection in animal models at therapeutically relevant doses. American
Wenk
34
Association of Geriatric Psychiatry, 15th Annual Meeting, Orlando, February, 2002.
Wenk, G.L., The neuroanatomy of Alzheimer’s disease. American Psychiatric Association,
Philadelphia, May, 2002.
Wenk, G.L., Marriott, L. and Hauss-Wegrzyniak, B. The influence of age and gender upon
the effects of chronic neuroinflammation. American Aging Association, 31st Annual Meeting,
San Diego, June, 2002.
Danysz, W., Moebius, H., Parsons, C., Quack, G., Wenk, G. and Stoeffler, A. Memantine
provides neuroprotection in animal models at therapeutically relevant doses. 8th International
Conference on Alzheimer’s Disease and Related Disorders. Stockholm, July, 2002.
Chen, K., Reiman, E.M., He, T., Galons, J.P., Stevenson, G., Hauss-Wegrzyniak, B.,
Trouard, T., Wenk, G.L. and Valla, J. Evaluation of an iterative principal component analysis for
detecting whole brain volume change in small animal magnetic resonance imaging. 8th
International Conference on Alzheimer’s Disease and Related Disorders. Stockholm, July,
2002.
Hauss-Wegrzyniak, B., Galons, J.P., Stevenson, G., Wenk, G.L., Chen, K., Reiman, E.,
Valla, J. and Alexander, G. Detecting an experimentally induced reduction in mouse brain
volume using sequential high-resolution MRI’s and the iterative PCA method. 8th International
Conference on Alzheimer’s Disease and Related Disorders. Stockholm, July, 2002.
Marriott, L.K., Benton, R.S., Hauss-Wegrzyniak, B., McGann, K. and Wenk, G.L. Dose
response of chronic neuroinflammation on behavior and neuropathology in female rats. Society
for Neuroscience, Orlando, November, 2002.
Rosi, S., Hauss-Wegrzyniak, B., McGann, K. and Wenk, G.L. The role of adenosine
receptors in the treatment of neuroinflammation with a NO-NSAID. Society for Neuroscience,
Orlando, November, 2002.
Chen, K., Reiman, E.M., He, T., Galons, J.P., Hauss-Wegrzyniak, B., Stevenson, G., Valla,
J., Trouard, T., Wenk, G.L. and Alexander, G.E. Improved iterative principal component
analysis for detecting whole brain atrophy from sequential mouse MRI's. Society for
Neuroscience, Orlando, November, 2002.
Wenk, G. L. Inflammation in Alzheimer’s disease: its role and an opportunity for therapy.
Winter Conference on Brain Research, Snowbird, January, 2003.
Danysz, W., Moebius, H., Parsons, C., Quack, G., Wenk, G. and Stoeffler, A. Memantine
provides neuroprotection in animal models at therapeutically relevant doses. American Society
for Neurochemistry, Newport Beach, CA, May, 2003.
Wenk, G.L. Neuropathologic basis for pharmacologic interventions in Alzheimer’s disease.
Wenk
35
American Psychiatric Association, 156th Annual Meeting, San Francisco, May, 2003.
Wenk, G.L. The role of neuroinflammation in Alzheimer's Disease: Insights from
an animal model. World Events Forum, Challenging Views of Alzheimer’s Disease, Round 2,
Cincinnati, July, 2003.
Danysz, W., Moebius, H.-J., Parsons, C., Quack, G., Wenk, G. and Banerjee, P.,
Memantine provides neuroprotection in animal models at therapeutically relevant doses.
International Psychogeriatric Association, Chicago, August, 2003.
Wenk, G.L., Inflammation in Alzheimer’s disease: its role and an opportunity for therapy.
First International Conference of Brain Aging, Bucharest, Romania, October, 2003.
Danysz, W., Parsons, C.G., Kalvinsh, I., Kauss, V., Jirgensons, A. and Wenk, G., A novel
class of amino-alkylcyclohexanes as NMDA receptor antagonists – in vivo characterization.
Society for Neuroscience, New Orleans, November, 2003.
Rosi, S., Ramirez-Amaya, V., Barnes, C.A, Hauss-Wegrzyniak, B., Worley, P.F. and Wenk,
G.L. Altered Arc immediate early gene protein expression during chronic brain inflammation in
the hippocampus. Society for Neuroscience, New Orleans, November, 2003.
Wenk, G.L., McGann, K., Hauss-Wegrzyniak, B. and Rosi, S. The toxicity of tumor necrosis
factor-α upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in
the regulation of inflammation: implications for Alzheimer’s disease. Society for Neuroscience,
New Orleans, November, 2003.
Hauss-Wegrzyniak, B., Rosi, S and Wenk, G.L. Chronic brain inflammation leads to a
decline in hippocampal NMDA R1 receptors that might underlie a component of the memory
deficit in patients with Alzheimer’s disease. Society for Neuroscience, New Orleans, November,
2003.
Marriott, L.K. and Wenk, G.L. Chronic and fluctuating administration of estrogen alter
estrogen receptor levels in response to chronic inflammation. Society for Neuroscience, New
Orleans, November, 2003.
Wenk, G.L., McGann, K., Hauss-Wegrzyniak, B. and Marriott, L.K. Neuroinflammation and
Alzheimer’s disease: an opportunity for therapy. International College of Geriatric
Psychoneuropharmacology, San Juan, PR, December, 2003.
Wenk, G.L., Natural products for memory enhancement: Still just a dream. Winter
Conference on Neural Plasticity. 16th Annual Meeting. St. Lucia, February, 2004.
Wenk, G.L, McGann-Gramling, K.R., Hauss-Wegrzyniak, B. and Marriott, L.K.
Neurobiological consequences of chronic and variable estrogen therapy in the presence of long
Wenk
36
term neuroinflammation. 9th International Conference on Alzheimer’s Disease and Related
Disorders. Philadelphia, July, 2003.
Rosi, S., Pert, C.B., Ruff, M.R., McGann-Gramling, K. and Wenk, G.L. DAPTA Targets
CCR5 Chemokine Receptors and Suppresses Microglial Activation in a Neuroinflammatory Rat
Model of Alzheimer's Disease. 9th International Conference on Alzheimer’s Disease and Related
Disorders. Philadelphia, July, 2003.
He, T., Chen, K., Reiman, E.M., Hicks, C., Trouard, T., Galons, J.-P., Hauss-Wegrzyniak,
B., Stevenson, G.D., Valla, J., Wenk, G.L. and Alexander, G.E. The Computation of MannitolInduced Changes in Mouse Brain Volume Using Sequential MRI and an Iterative Principal
Component Analysis. 9th International Conference on Alzheimer’s Disease and Related
Disorders. Philadelphia, July, 2003.
Ongini, E., McGann-Gramling, K., Hauss-Wegrzyniak, K., Ronchetti, D., Maucci, R., Rosi,
S., Gasparini, L. and Wenk, G.L. A Nitric Oxide-Releasing Derivative of the Antioxidant Ferulic
Acid, NCX 2057, Attenuates Chronic Neuroinflammation in Rat. 9th International Conference on
Alzheimer’s Disease and Related Disorders. Philadelphia, July, 2003.
Rosi, S., Vazdarjanova, A., Ramirez-Amaya, A., Worley, P.F., Barnes, C.A. and Wenk,
G.L. Neuroinflammation disrupts Arc immediate early gene expression in the DG. Society for
Neuroscience, San Diego, October, 2004.
Wenk, G.L. Translating pharmacokinetic insights into Alzheimer disease clinical practice.
American Society for Consultant Pharmacists, 35th Annual Meeting, San Francisco, November,
2004.
Wenk, G.L. Clinical practice evidence supported by the pathological cascade of
Alzheimer’s disease. American Association for Geriatric Psychiatry, 18th Annual Meeting, San
Diego, March, 2005.
Wenk, G.L. Mechanisms of action of memantine: neuroprotection and cognition
enhancement by NMDA channel antagonism. Memantine Consultant’s Form, Miami, October,
2005.
Hasler, B.P., Cousins, J.C., Fridel, K.W., Wenk, G. and Bootzin, R.R. Effect of sleep
treatment on circadian rhythms in adolescents with a history of substance abuse. American
Academy of Sleep Medicine and Sleep Research Society, vol 28, 2005.
Wenk, G.L., Rosi, S. and Danysz, W. Memantine: Mechanisms of neuroprotection and
cognition enhancement in Alzheimer’s disease. Society for Neuroscience, Washington D.C.,
November, 2005.
Marchalant, Y., Rosi, S. and Wenk, G.L. Anti-inflammatory property of the cannabinoid
agonist WIN-55212-2 in a neuroinflammation rat model of Alzheimer disease. Society for
Wenk
37
Neuroscience, Washington D.C., November, 2005.
Rosi, S., Vazdarjanova, A., Ramirez-Amaya, V., Marchalant, Y., Worley, P.F., Barnes, C.A.
and Wenk, G.L. The consequences of Neuroinflammation upon hippocampal activity patterns
can be reversed by a low affinity open channel NMDAR antagonist: memantine. Society for
Neuroscience, Washington D.C., November, 2005.
Burke, S.N., Maurer, A.P., Insel, N., Navratilova, Z., McNaughton, B.L., Wenk, G.L. and
Barnes, C.A. Effects of memantine on experience-dependent place field expansion in aged rats.
Society for Neuroscience, Washington D.C., November, 2005.
Wenk, G.L. The Neuroinferno: Chronic Brain Inflammation, 29th Annual Winter
Conference on Brain Research, Steamboat Springs, January, 2006.
Marchalant, Y., Rosi, S. and Wenk, G.L. Anti-Inflammatory actions of the
endocannabinoid system in a rodent model of chronic neuroinflammation. 10th International
Conference on Alzheimer's Disease and Related Disorders, Madrid, July, 2006.
Rosi, S. and Wenk, G.L. Neuroinflammation and Alzheimer's disease: The early events
leading to neurodegeneration. 10th International Conference on Alzheimer's Disease and
Related Disorders, Madrid, July, 2006.
Danysz, W., Wenk, G.L., Banerjee, P., Parsons, C.G. Preclinical basis for memantine
efficacy in Alzheimer's disease. European Behavioral Pharmacology Society, Cracow, Poland,
September, 2006.
Marriott, L.K., McGann-Gramling, K.R., Hauss-Wegrzyniak, B., Sheldahl, L.C., Shapiro,
R.A., Dorsa, D.M. and Wenk, G.L. Suppression of ERα by constant, but not pulsed, estrogen
replacement occurs in a region- and time-dependent manner. Society for Neuroscience,
Atlanta, November, 2006.
Cerbai, F., Marchalant, Y., Brothers, H. and Wenk, G.L. Do endocannabinoids regulate
the MAP Kinase pathway on inflammation and aging? Society for Neuroscience, Atlanta,
November, 2006.
Marchalant, Y., Cerbai, F., Brothers, H. and Wenk, G.L. Endocannabinoid agonist effects
on inflammation and aging in rats. Society for Neuroscience, Atlanta, November, 2006.
Brothers, H., Marchalant, Y., Cerbai, F. and Wenk, G.L. The effects of the adenosine
receptor antagonist caffeine upon neuroinflammation: Implications for Alzheimer's and
Parkinson's disease. Society for Neuroscience, Atlanta, November, 2006.
Rosi, S. Ramirez-Amaya, V., Rivera, E.E., Vazdarjanova, A., Wenk, G.L., Worley, P.F.
and Barnes, C.A. CA1 hippocampal networks remain stable during chronic neuroinflammation.
Society for Neuroscience, Atlanta, November, 2006.
Wenk
38
Cerbai, F., Marchalant, Y., Brothers, H. and Wenk, G.L. The regulation of brain
inflammation via neuron-glia communication, First Annual International Brain Conference,
IBRO, Orlando, January, 2007.
Wenk, G.L. The role of glutamate in the inflammatory processes in Alzheimer’s disease.
III Neurotoxicity Society, Pucon, Chile, March, 2007.
Marchalant, Y., Cerbai, F., Brothers, H.M. and Wenk, G.L. Cannabinoid receptor
stimulation is anti-inflammatory and improves memory in old rats. 17th International
Cannabinoid Research Society, Québec, Canada, June, 2007.
Milliken, H.L., Rosi, S., Wenk, G.L. and Barnes, C.A. Behaviorally-induced immediate
early gene Arc expression in the Entorhinal Cortex of the rat: deep versus superficial layers.
Society for Neuroscience, San Diego, November, 2007.
Rosi, S., Ramirez, V., Esperanza, E., Wenk, G.L. and Barnes, C.A. Stability of
hippocampal networks depends upon the presence of activated microglial cells. Society for
Neuroscience, San Diego, November, 2007.
Cerbai, F., Marchalant, Y., Brothers, H.M. and Wenk, G.L. Mechanisms underlying the
failure of neurons and microglia to regulate brain inflammation. Society for Neuroscience, San
Diego, November, 2007
Brothers, H.M., Marchalant, Y., Cerbai, F. and Wenk G.L. Dose-dependent effects of the
adenosine receptor antagonist caffeine upon neuroinflammation: Implications for Alzheimer's
and Parkinson's disease. Society for Neuroscience, San Diego, November, 2007
Marchalant, Y., Brothers, H.M., Cerbai, F. and Wenk, G.L. Endocannabinoids receptors
effects on neuroinflammation and memory in aged rats. Society for Neuroscience, San Diego,
November, 2007.
Marriott, L.K., McGann-Gramling, K.R., Hauss-Wegrzyniak, B., Sheldahl, L.C., Shapiro,
R.A., Dorsa, D.M. and Wenk, G.L. Long-term constant and pulsed estrogen replacement
regimens differentially regulate ER, HSP and PR protein levels in the hypothalamus and uterus.
Society for Neuroscience, San Diego, November, 2007.
Marchalant, Y., Brothers, H.M., and Wenk, G.L. Neuroinflammation in young and aged
rats: Influence of endocannabinoids, memantine and caffeine. International Neuroimmunology
Symposium, Dublin, Ireland, March, 2008.
Wenk, G.L., Brothers, H.M., Cerbai, F. and Marchalant, Y. Neuron-glia
intercommunication during neuroinflammation associated with Alzheimer’s disease and other
neurodegenerative disorders. International Behavioral Neuroscience Society, St. Thomas, US
Virgin Islands, June, 2008.
Wenk
39
Cerbai, F., Marchalant, Y., Giovannini, M.G. and Wenk, G.L. Role of CD200 in neuronglia intercommunication during inflammation. Federation of European Neuroscience Societies,
Forum 2008, Geneva, Switzerland, July, 2008.
Marchalant, Y., Brothers, H.M., and Wenk, G.L. Role of endocannabinoids on
neuroinflammation, memory and neurogenesis in aged rats. 11th International Conference on
Alzheimer's Disease and Related Disorders, Chicago, July, 2008.
Brothers, H.M., Marchalant, Y., and Wenk, G.L. Regional susceptibility to inflammation:
neuron-glia interactions in the hippocampus and substantia nigra and rescue by the NMDA
antagonist memantine. 11th International Conference on Alzheimer's Disease and Related
Disorders, Chicago, July, 2008.
Marchalant, Y., Wenk G.L., Burgess, L. and Brothers, H.M. Coffee and marijuana may
prevent Alzheimer’s and Parkinson’s disease. Society for Neuroscience, Washington, D.C.,
November, 2008.
Brothers, H.M., Marchalant, Y., Burgess, L., Turner, S. and Wenk G.L. The
consequences of chronic neuroinflammation in the hippocampus and substantia nigra are
attenuated by memantine. Society for Neuroscience, Washington, D.C., November, 2008.
Marchalant, Y., Brothers, H.M., Burgess, L. and Wenk G.L. Endocannabinoid effects on
neuroinflammation and neurogenesis in aged rats. Society for Neuroscience, Washington,
D.C., November, 2008
Wenk, G.L. Aging of inflammatory system as a contributing factor to AD - therapeutic
perspectives. IV Neurotoxicity Society, Arica, Chile, April, 2009.
Marchalant, Y., Brothers, H.M., Mitchem, M., Kaercher, R., Turner, S. and Wenk, G.L.
Cannabinoids or endocannabinoids: What benefits on neuroinflammation and neurogenesis?
Gordon Conference: Cannabinoid function in the CNS, University of New England, August,
2009.
Brothers, H., Kaercher, R., Marchalant, Y., Turner, S. and Wenk, G.L. Chronic
neuroinflammation reproduces characteristics of Parkinson’s disease in the substantia nigra,
locus coeruleus, and raphe nucleus. Society for Neuroscience, Chicago, October, 2009
Marchalant, Y., Brothers, H., Mitchem, M., Kaercher, R., Turner, S. and Wenk, G.L.
Cannibinoids versus endocannabinoids in aging rats: which could benefit more to
neuroinflammation and neurogenesis? Society for Neuroscience, Chicago, October, 2009
Wenk
40
Wenk, G.L., Del Soldato, P., Brothers, H. and Marchalant, Y. Hydrogen sulfide-donatingdiclofenac and –L-DOPA effectively reduce neuroinflammation in aged rats. Society for
Neuroscience, Chicago, October, 2009
Marchalant, Y., Brothers, H.M., Dipatrizio N., Kaercher, R., Mitchem, M., and Wenk, G.L.
Effects of chronic FAAH inhibition using URB597 on neuroinflammation and neurogenesis in
aged rats. Society for Neuroscience, San Diego, November, 2010.
Brothers, H.M., Kaercher, R., Mitchem, M., Turner, S., Marchalant, Y. and Wenk, G.L.
Time-dependant recovery from a neuroinflammation-induced spatial memory deficit corresponds
with increased SNAP25 expression in the hippocampus. Society for Neuroscience, San Diego,
November, 2010.
Giovannini, M., Cerbai, F., Lana, D., Pugliese, A., Nosi, D. and Wenk, G. Glia-neuron
interaction in the hippocampus of the rat is modified by aging and inflammation. Society for
Neuroscience, San Diego, November, 2010.
Bardou, I., Brothers, H.M., Marchalant, Y. and Wenk, G.L. Stimulation of endocannabinoid
receptors is required for reduction of neuroinflammation and restoration of neurogenesis in the
aged brain. International Conference on Alzheimer’s Disease, Paris, July, 2011.
Brothers, H.M., Bardou, I., Hopp, S. and Wenk, G.L Compensation for inflammationinduced spatial memory deficit by upregulation of GLT1 and SNAP25. International Conference
on Alzheimer’s Disease, Porte de Versailles, Paris, July, 2011.
Brothers, H.M., Hopp, S. and Wenk, G.L Elevated glutamate transport by GLT1 attenuates
inflammation-induced memory impairment. International Conference on Alzheimer’s Disease,
Porte de Versailles, Paris, July, 2011.
Wenk, G.L. and Brothers, H.M. The role of neuroinflammation in the determination of
regional and neuronal vulnerability in Alzheimer’s disease. International Conference on
Alzheimer’s Disease, Porte de Versailles, Paris, July, 2011.
Lana, D., Cerbai. F., Nosi, D., Petkova-Kirova, P., Zecchi, S., Brothers, H.M., Wenk, G.L.
and Giovannini, M.G. The neuron-astrocyte-microglia triad in normal brain aging and a model of
neuroinflammation in the rat. International Brain Research Organization, Florence, July, 2011.
Bardou, I., Brothers, H.M., Hopp, S.C., Emerman, A., Marchalant, Y. and Wenk, G.L. The
effects of cannabinoids on neuroinflammation, neurogenesis and memory in aged rats. Society
for Neuroscience, Washington, DC, November, 2011.
Brothers, H.M., Konradsson-Geuken, Å., Bardou, I., Bortz, D.M., Gash, C.R., Bruno, J.P.
and Wenk, G.L. Time-dependent effects of lipopolysaccharide-induced chronic
Wenk
41
neuroinflammation upon glutamate transporter expression as well as extracellular glutamate
levels and clearance measured second-by-second in the rat hippocampus. Society for
Neuroscience, Washington, DC, November, 2011.
Hopp, S.C. and Wenk, G.L. Age-related changes in the neuroinflammatory response to
IL1b. Society for Neuroscience, Washington, DC, November, 2011.
Bardou, I., Brothers, H.M., Hopp, S.C., Albin-Brooks, C., Chen, O. and Wenk, G.L.
Behavioral and biochemical consequences of chronic neuroinflammation in rats across ages. 8th
Federation of European Neuroscience Societies Forum. Barcelona, July, 2012.
Bardou, I., Brothers, H.M., Kaercher, R.M., Hopp, S.C., Albin-Brooks, C., Hammond, G.,
Holley, J., Chen, O. and Wenk, G.L. Chronic neuroinflammation across ages differentially
influences cellular and cognitive processes. Society for Neuroscience, New Orleans, October,
2012.
Kaercher, R.M., Bardou, I., Brothers, H.M., Hopp, S.C., Albin-Brooks, C., Hammond, G.,
Holley, J., Chen, O. and Wenk, G.L. Aged-related neuroinflammation differentially affects
cytokine levels and cognitive impairment. Society for Neuroscience, New Orleans, October, 2012.
Royer, S.E., Hopp, S.C., Kaercher, R.M., Adzovic, L., Brothers, H.M., Bardou, I. and
Wenk, G.L. The role of post-transcriptional control in age-associated enhancement of
inflammatory cytokine expression following acute intrahippocampal interleukin-1β. Society for
Neuroscience, San Diego, November, 2013.
Adzovic, L., Hopp, S.C., Kaercher, R.M., Royer, S.E., D’Angelo, H. and Wenk, G.L.
Neuroinflammation: pathological mechanisms and the beneficial role of insulin therapy. Society
for Neuroscience, San Diego, November, 2013.
Hopp, S.C., Kaercher, R.M., Royer, S., D’Angelo, H., Adzovic, L. and Wenk, G.L. The
effects of calcium dysregulation on neuroinflammation- and age-associated memory deficits.
Society for Neuroscience, San Diego, November, 2013.
Brothers, H.M., Bardou, I., Hopp, S.C., Kaercher, R.M. and Wenk, G.L. Riluzole partially
rescues age-associated, but not lipopolysaccharide-induced, loss of glutamate transporters and
spatial memory. Society for Neuroscience, San Diego, November, 2013.
Hopp, S.C., Kaercher, R.M., Royer, S., D'Angelo, H., Adzovic, L. and Wenk, G.L. The role
of calcium dysregulation in neuroinflammation- and age-associated memory deficits. Miami 2014
Winter Symposium, The Molecular Basis of Brain Disorders, January 2014.
Adzovic, L., Hopp, S.C., Crockett, A., D’Angelo, H., Royer, S., Lynn, A.E. and Wenk, G.L.
The effects of insulin in the brain and its effects in influencing the neuroinflammatory response
and the memory in young and aged rats. Miami 2014 Winter Symposium, The Molecular Basis of
Brain Disorders, January 2014.
Wenk
42
INVITED SYMPOSIA AND COLLOQUIA:
Mechanisms of Neurotoxicity, Johns Hopkins University School of Hygiene and Public Health,
Department of Environmental Health Sciences, Baltimore, October, 1983.
23rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto
Rico, December, 1984.
Towson State University, Sigma Xi Chapter Meeting, Towson, October, 1984.
Johns Hopkins University, Dept. of Psychology, Baltimore, November, 1984.
Principles and Mechanisms of Neurotoxicity, Johns Hopkins University School of Hygiene and
Public Health, Department of Environmental Health Sciences, Baltimore, November, 1984.
The Wellcome Research Laboratories, Burroughs-Wellcome Pharmaceutical Co., Research
Triangle Park, January, 1985.
Pfizer Laboratories, Groton, January, 1985.
Johns Hopkins University, Memory, Amnesia and Brain Function, February, 1985.
Maryland Science Institute, Baltimore, MD, March, 1985
Hoechst-Roussel Pharmaceuticals Inc., Somerville, April, 1985.
University of Florence, Department of Pharmacology, Italy, May 1985.
Symposium on Cognition and Memory, IVth World Congress of Biological Psychiatry,
Philadelphia, September, 1985.
National Institutes of Health, NIA, Laboratory of Neurosciences, Bethesda, April, 1986
St. Mary's College, Department of Biology, St. Mary's City, MD, April, 1986
Brazilian Society for Biological Psychiatry, Belo Horizonte, Brazil, November, 1986
Neuroscience Sector, Universidade Federal Fluminense, Niteroi, Brazil, November, 1986
American College of Neuropsychopharmacology, Washington, D.C., December, 1986
Winter Conference on Brain Research, Vail, CO, January, 1987
Italian Study Group on Brain Aging, Sirmione, Italy, April, 1987
Wenk
43
Structural-Functional Properties of the Basal Forebrain Cholinergic System, Session Chair,
Leipzig, DDR, August, 1987.
Department of Psychology, Psi Chi, Towson State University, March, 1988.
Psychopharmacology: An Up To Date. Association for the Advancement of Neurosciences,
Rome, September, 1988.
13th Annual Winter Conference on the Neurobiology of Learning and Memory, Session Chair,
Park City, Utah, January, 1989.
University of California, Department of Psychobiology & The Center for the Neurobiology of
Learning and Memory, Irvine, CA, January, 1989.
University of Southern California, Department of Psychology, Los Angeles, CA, February, 1989.
Case Western Reserve, Department of Psychology, Cleveland, OH, March, 1989.
Symposium on NMDA Receptors and Behavior, Session Chair and Organizer, 2nd
Neuroscience Winter Conference, St. Maartin, Netherlands Antilles, February, 1990.
University of Arizona, Departments of Anatomy, Neurology, and Psychology, Tucson, March,
1990.
Princeton University, Department of Psychology, Fourth Annual New Jersey
Neuropsychopharmacology Society meeting, May, 1990.
Fourth Conference on the Neurobiology of Learning and Memory, Session Chair: Neural
Systems, Irvine, CA, October, 1990.
Dartmouth Medical School, Department of Physiology, Hanover, NH, April, 1991.
Society for Neuroscience, Satellite Symposium: Neurotransmitter Interactions and Cognitive
Function, New Orleans, November, 1991.
NIH Concept Review Panel, Participant for Neuroscience and Neuropsychology of Aging
Program, National Institute on Aging, "Resources for Rodent and Primate Testing of Drugs for
Cognitive Activity and a Resource for Toxicological Screening of Newly Developed
Compounds." December, 1991.
First Symposium on "The Glutamate Hypothesis of Dementia," A satellite meeting of the
Second European Stroke Conference, Lausanne, Switzerland, June, 1992
British Association for Psychopharmacology & European Behavioral Pharmacology Society,
"Neurotransmitter Interactions with Cholinergic Function in Learning and Memory," Cambridge,
Wenk
44
U.K., August, 1992.
The Aging Monkey: Behavior and Neurobiology. Johns Hopkins University School of Medicine,
"Age-related changes in monkey and rodent neurochemistry," Baltimore, November, 1992.
Wayne State University, Biopsychology and Neuroscience Program, "Animal model of
Alzheimer's Disease: What have they taught us?" Detroit, April, 1993
Winter Conference on Neural Plasticity, "Neuropeptides in Memory Processes," Co-Chair.
Granada, Caribbean, February, 1994.
Joint International Child Neurology Association/Child Neurology Society Satellite Symposium,
"Molecular and Neurobiology of Rett Syndrome," Oregon Health Sci. University, October, 1994.
19th Annual Winter Conference on the Neurobiology of Learning and Memory, "Tribute to David
Olton," Park City, Utah, January, 1995.
4th Annual Psychopharmacology Review, Conference Faculty Member, University of Arizona
Department of Psychiatry, Tucson, AZ, February, 1995.
Takeda Chemical Industries, Ltd., Pharmaceutical Research Division, Animal models of
Alzheimer's Disease and Cognitive Enhancers, Osaka, Japan, July, 1995.
University of Kuopio, Departments of Neurology and Neuroscience, Animal models of
Alzheimer's Disease: The role of neuroprotection, Kuopio, Finland, September, 1995.
5th Annual Psychopharmacology Review, Conference Faculty Member, University of Arizona
Department of Psychiatry, Tucson, AZ, February, 1996.
University of Kuopio, Kuopio Summer School in Neurosciences, Neurobiological Basis of
Cognitive Decline in Aging, Kuopio, Finland, May, 1996.
6th Annual Psychopharmacology Review, Conference Faculty Member, University of Arizona
Department of Psychiatry, Tucson, AZ, February, 1997.
University of Florence, Department of Pharmacology, Animal models of Alzheimer’s Disease,
Florence, Italy, August, 1997.
Parke-Davis, Department of Neurological & Neurodegenerative Diseases, Chronic
neuroinflammation as an animal model of Alzheimer’s Disease, Ann Arbor, MI, January, 1998.
7th Annual Psychopharmacology Review, Conference Faculty Member, University of Arizona
Department of Psychiatry, Tucson, AZ, February, 1998.
University of Irvine, Center for the Neurobiology of Learning and Memory, Animal models of
Wenk
45
Alzheimer’s Disease: The role of chronic neuroinflammation, Irvine, CA, March, 1998.
Department of Psychology, University of Arizona, Useful animal models of Alzheimer’s Disease.
September, 1998.
Southern Arizona Psychological Association, “Back to School III,” An Update on Novel Animal
Models of Alzheimer’s Disease. January, 1999.
8th Annual Psychopharmacology Review, Conference Faculty Member, University of Arizona
Department of Psychiatry, Tucson, AZ, February, 1999.
Department of Psychology, University of Arizona, “Memory: Use It or Lose It” series for the
University of Arizona Senior Academy. March, 1999.
West Coast College of Biological Psychiatry, “The role of neuroinflammation in the aging brain,”
Tucson, Arizona, April, 1999.
Institute of Neuroscience, University of Pierre and Marie Curie, CNRS, “The role of
neuroinflammation in a novel animal model of Alzheimer’s Disease,” Paris, June, 1999.
Department of Pharmacology, University of Florence, “Alzheimer’s Disease: The role of
neuroinflammation and potential therapies,” Italy, October, 1999.
24th Annual Winter Conference on the Neurobiology of Learning and Memory, "Nicotine:
Possible role in learning, memory and Alzheimer’s Disease," Park City, Utah, January, 2000.
Neuroinflammation in Alzheimer’s Disease, Session chair: “Future Directions,“ Washington,
D.C, July, 2000.
10th Annual Psychopharmacology Review, Conference Faculty Member, “Cognitive
Enhancers.” University of Arizona Department of Psychiatry, Tucson, AZ, February, 2001.
“Brain Science 101” Course faculty, Tucson Chapter for the Society for Neuroscience, Tucson,
AZ, March, 2001.
Iowa State University, Department of Biomedical Sciences, “The role of inflammation in
Alzheimer’s Disease.” Ames, IA, April, 2001.
Capri Symposium on NO-NSAIDs. “The use of NO-NSAIDs in the prevention of the pathalogy
and dementia associated with Alzheimer's Disease." Capri, Italy, May, 2001.
Palo Verde Behavioral Health, Tucson Medical Center, “Cognitive enhancers, CNS herbals and
placebos,” June, 2001.
Southern Arizona Veterans Affairs, Tucson, “Cognitive enhancers and CNS herbals: are they
Wenk
46
effective, or just placebo?” August, 2001.
Canyon Ranch, Tucson, “Cognitive enhancers and CNS herbals” 2001-2003.
Chairman, Special Interest Social, Behavioral and Cognitive Neuroscience, Society for
Neuroscience. San Diego, November, 2001.
National Institute on Aging, Behavioral Neuroscience Section, Laboratory of Neurosciences
Gerontology Research Center, “Animal models of chronic brain inflammation: what have they
taught us about Alzheimer’s disease?” Baltimore, July, 2002.
University of Lisbon, Laboratory of Neuroscience, Faculty of Medicine, “Animal models of
Alzheimer’s disease and the role of brain inflammation.” Lisbon, Portugal, October 2002.
Update on Autism, Harvard University Autism Study Group, “The cholinergic system in Autism.”
Boston, October 2002.
National Institute of Environmental Health Sciences, “Glial mediated neurotoxicity as a model of
Alzheimer’s disease.” Laboratory of Pharmacology and Chemistry 2003 Seminar Series,
Environmental Toxicology Program, Research Triangle Park, NC, April, 2003.
University of Alabama at Birmingham School of Medicine, Continuing Medical Education (CME)
satellite symposium, “Transforming Primary Care for Alzheimer’s Disease: New Treatment
Strategies on the Horizon”. Pre-Med Mid-West Conference and Exposition, Rosemont, IL, June,
2003.
Veteran’s Administration, “Alzheimer’s Disease.” Tucson, July 2003.
National Institute of Mental Health, Laboratory of Behavioral Neuroscience, “Animal models of
Alzheimer’s disease and the role of brain inflammation.” Bethesda, October, 2003
Veterans Administration & Salt Lake City Health Care System, Update on
Psychopharmacology, “Psychopharmacology of Cognitive Enhancement: Myths and facts.” Salt
Lake City, March, 2004.
University of Utah, Department of Psychology, “Animal models of brain inflammation,” Salt Lake
City, March, 2004.
Ohio State University, Department of Psychology, “Animal models of Alzheimer’s disease: the
role of neuroinflammation,” Columbus, November, 2004.
29th Annual Winter Conference on the Neurobiology of Learning and Memory, "Memantine and
neuroprotection," Park City, Utah, January, 2005.
Wenk
47
University of South Florida, Alzheimer's Research Laboratory, Department of Pharmacology,
“Animal models of Alzheimer’s disease: the role of neuroinflammation,” Tampa, January, 2005.
Merz Pharmaceuticals; Memantine: Mechanism of Action in Alzheimer's Disease; Facts,
Hypothesis and Communication Strategy, “A potential mechanism of action of memantine to
explain the reduction in neuronal noise and cognitive improvement.” Cloister Eberbach,
Frankfurt, Germany, February, 2005.
American Association for Geriatric Psychiatry, Translating Alzheimer’s Disease Research into
Clinical Practice: From Genomics to Neuropathology, “Neuropathological changes in
Alzheimer’s disease: potential targets for treatment.” San Diego, March, 2005.
Department of Oral Biology, Ohio State University, September, 2005
Molecular Virology, Immunology & Molecular Genetics Internal Faculty Seminars, Ohio State
University, October, 2005
Neuroscience Graduate Student Program, Ohio State University, October, 2005
Department of Anatomy and Neurobiology, Boston University School of Medicine, September,
2006.
Department of Neuroscience, Case Western Reserve University, February, 2007.
Central Ohio Case Management Network, “Current research on neurodegenerative disorders,”
March, 2007.
Department of Neuroscience, Cleveland Clinic Research Foundation, “The NeuroInferno: The
role of brain inflammation in Alzheimer’s disease.” June, 2007.
Sanders-Brown Center on Aging, University of Kentucky, “The role of neuroinflammation in
Alzheimer’s disease.” October, 2007.
Central Ohio Case Management Network, “Brain Aging.” October, 2007.
Organizer: Preceptorship for Forest Pharmaceuticals - Preclinical Research Targeting the
Prevention and Treatment of Alzheimer’s Disease. Department of Psychology, OSU. November
28-29, 2007.
Wenk
48
University of Missouri, Translational Neuroscience Symposium, “Translating animal studies on
brain inflammation into treatments for Alzheimer’s Disease.” March, 2011.
Tucson Unified School District, “How marijuana, food and medications affect our brain and
behavior. March, 2011.
Annual conference on The Psychology of Health, Immunity and Disease. The National Institute
for the Clinical Application of Behavioral Medicine, December, 2011, Hilton Head, S.C.
Oregon Health Sciences University, Science Education and Brain Awareness, January, 2012.
DragonFlyLearning Webinar, Campus Outreach Services, “Defining Nutrition in a World of
Chemicals” February. 2012
OSU Women & Philanthropy, Naples & Sarasota, FL. February. 2012
The Seventh National Clinical Conference on Cannabis Therapeutics, April, 2012, Tucson, AZ
Southern Illinois University Carbondale, Center for Integrated Research in Cognitive and Neural
Sciences, “Calming the neuroinferno with drugs and food.” October, 2013.
Wenk
49
MEDIA COVERAGE OF RESEARCH:
Movie:
Interviewed and filmed in New York for Lucasfilm, Ltd. and Amanada Productions for a two-hour
TV documentary entitled: "Project Millennium." Topic: Cognitive enhancers and drug use in the
future. January, 1991.
Television:
Interviewed by Cable News Network (CNN), Turner Broadcasting Co., KUAT (PBS) & KOLD
(CBS), Tucson affiliates, on the implications of my research for the treatment of Alzheimer's
disease. Spring-Fall, 1992. Guest on the "Doctor Dean" show for NBC-TV affiliate KGO in San
Francisco, CA, (9/92). Interviewed by "Life Choices," Medical Programs for Cable Television,
(11/93). Phone interview by ABC News Magazine "Day One" on mechanisms of memory
enhancement. KOLD (CBS) on caffeine, (9/96); on dietary restriction, (1/97); on caffeine again,
(2/98). KGUN (ABC) (3/98), on foods that influence mood. KGUN (ABC) videotaped my
lectures on hallucinogens, (3/98). KUAT (PBS) on addiction, (3/98); KGUN (ABC) (4/98), on the
effects of caffeine. KVOA (NBC) on the use of super-aspirins in AD (12/98). KVOA (NBC) on
the effects of chocolate on brain chemistry (2/99). KUAT “Arizona Illustrated” (PBS) Update on
Alzheimer’s Disease (2/99); KOLD (CBS) on caffeine, (5/99); KOLD (CBS) on the effect of
nutrients upon brain function, (2/00); KUAT “Arizona Illustrated” (PBS) Update on antiinflammatory therapies for Alzheimer’s Disease (10/00) KVOA (NBC) on the effects of alcohol
on the brain, (12/00); KOLD (CBS) interview on movie review for “Human Nature.” (4/02).
Invited Expert for Sharecare: online health and wellness platform created by Dr. Mehmet Oz,
Jeff Arnold, Harpo Studios (Oprah) and Discovery Communications.
Radio:
Interviewed by National Public Radio (NPR) for program entitled: "Thinking about thinking about
thinking;" and by WBZ (Boston), WJR (Detroit) and KABC (Los Angeles) on impact of "smart
drugs" on human cognition and by KRBS (Tucson) on recent treatments for Alzheimer's
disease. Pacifica Radio, San Francisco, on cognitive enhancers and memory impairments
associated with aging. NPR, Todd Mundt Show, interview on Gingko, April 2003. NPR Science
Friday, October 2006 & December 2006.
Journal, Magazine or Newspaper:
Interviewed by Robert Kanigel for an article: "Specimen No. 1913. A rat's brief life in the service
of science," in The Sciences, (NYAS), January/February, pp. 30-37, 1987; Interviewed by Omni
Magazine (four times), Discover Magazine, Headlines Magazine, Health Magazine, The Arizona
Daily Star (two times) & The Harvard Newsletter for articles on cognitive enhancers, "smart
drugs" and aging. Arizona Republic on nutrition and aging. Men's Health, issue on how diet
and drugs can influence brain health (Feb 1998). Childhood Magazine, on the effects of
caffeine and sugar upon mood in children (1998); Arizona Daily Star, Daily Wildcat & Sierra
Vista Herald on super-aspirins for AD (12/98); University of Arizona Alumni Magazine (4/99) on
super-aspirin research; Clinical Psychiatry News, (6/01) on Gingko biloba’s effect on cognition;
Newsweek, (6/02) on action of NMDA antagonists such as memantine for treatment of AD; UPI
on ERT in AD. Wall Street Journal (3/03) on the potential mechanism of action and use of
Wenk
50
memantine for the treatment of AD; Benefits of ginkgo biloba, WebMD (4/03). Practical
Neurology on alternative treatments in medicine (6/03);Technology Review (Germany) on
cognitive enhancers (7/03). Marijuana and Alzheimer’s disease coverage by: Health Day, Time,
Reuters, WebMD, CBS News, Nature, New York Daily News. Worth Magazine, Energy Drinks
and Cognition, (2/09).
Wenk
51
RESEARCH GRANTS
Department of Defense, DAMD 17 82 C 2225, "Neurochemical mechanisms mediating recovery
of function," Co P.I.s - Gary Wenk, David Olton, Zoltan Annau; Total Award: $561,644; 11/01/82
-10/31/85.
Burroughs-Wellcome Pharmaceutical Co., "Investigations of cognition enhancing agents," P.I. Gary Wenk; Total Award: $16,688.
National Institute of Aging, 5 P50 AG 05l46, "Alzheimer's Disease Research Center," P.I. Donald Price, Total Award: $950,000; 09/0l/84 - 03/8l/87.
National Institute of Health, 5 P50 NS 2047l, "The Forebrain Cholinergic System in Health and
Disease," P.I. - Donald Price, Total Award: $l99,000; 04/0l/84 - 03/3l/87.
National Institute of Health, 5 P50 NS 20471, "Disorders of Memory and Motor Performance
Associated With Aging" P.I. - Donald Price; Total Award: $4,649,584; Percent of time: 35%;
07/01/87 - 06/30/92.
National Institute of Health, 1 PO1 HD 23540, "Rett Syndrome: Genetics, Pathogenesis and
Search For Marker," P.I. - Hugo Moser; Total Award: $1,705,901; Percent of Time: 15%;
12/01/87-11/30/90.
National Science Foundation, BNS 88 07010, "Cholinergic-Serotonergic Interactions That
Underlie Behavior," P.I. - Gary Wenk; Total Award: $88,954; Percent of Time: 17%; 09/01/88 12/31/90.
National Institute of Health, 5 P01 NS 26643, "Research Centers for AIDS Dementia and Other
Retrovirus-Associated Neurological Disorders," P.I. - Richard Johnson; Total Award:
$13,071,528; Percent of Time: 15%; 07/01/88 -06/30/93.
Otsuka Pharmaceutical Co., Ltd., Japan, "Evaluation of the therapeutic benefits of OPC-14417:
Age-related cognitive impairments," P.I. - Gary Wenk; Total Award: $81,045; 1990-1991.
Sigma Tau Farmaceutiche, Italy, "Investigations of the cognition enhancing properties of acetyll-carnitine," Co P.I.s - Gary Wenk, David Olton; Total Award: $132,758; 1990-1992.
Gliatech Inc., Cleveland, OH, "Investigations of the cognition enhancing properties of histamine
antagonists," P.I.- Gary Wenk; Total Award: $30,335; 1992.
National Institute of Health, PO1 HD 23540, "Pathogenesis of Rett Syndrome," P.I. - Hugo
Moser; Total Award: $3,041,488; Percent of Time: 20%; 12/01/90 - 11/30/93.
National Science Foundation, BNS 89 14941, "Basal Forebrain: Differential Vulnerability and
Function," P.I.- Gary Wenk; Total Award: $165,000: Percent of Time: 15%; 09/15/90 - 08/01/94.
Wenk
52
National Science Foundation, BNS 89 14941, Research Enhancement for Undergraduates,
P.I.- Gary Wenk; Total of two separate awards: $8,000, 1995.
International Rett Syndrome Association, "Rett Syndrome: Neurochemical Investigations," P.I.Gary Wenk; Total Award: $19,945; 1995-1996.
Research for Rett Syndrome Foundation, Inc., Partial support for equipment purchase; P.I.Gary Wenk; Total Award: $1000; 1995.
Merz + Co., Frankfurt, Germany, "Evaluation of the neuroprotective abilities of Memantine," P.I.Gary Wenk; Total Award: $44,672; 1995.
Vernon and Virginia Furrow "Innovations in Medical Education Grant," to purchase "Slice of
Brain," a videodisc-based instructional technology to improve teaching of human neuroscience;
$2960, April, 1995.
National Institute of Mental Health, National Research Service Award to Dr. James Stoehr.
Sponsor - Gary Wenk; Total Award: $47,400; 1994-1996.
International Rett Syndrome Association, "Rett Syndrome: Neurochemical Investigations," P.I.Gary Wenk; Total Award: $19,939; 08/01/95 - 07/31/96.
National Institute of Aging, RO1 AG 10546, "Aging Vulnerability to Excitatory Amino Acids," P.I.
-Gary Wenk; Total Direct Costs: $264,458; Percent of Time: 20%; 04/01/94 - 09/30/97.
Arizona College of Osteopathic Medicine/ Midwestern University, Effects of manipulations of the
basal forebrain cholinergic system on behavioral and neurochemical markers in young and old
rats. Co - P.I.s, Gary Wenk & James Stoehr. Total Award: $20,000; 11/01/96-10/31/97.
Cephalon, Inc., A novel animal model of Alzheimer’s Disease: chronic neuroinflammation in the
presence of an overexpression of beta amyloid protein. P.I. Gary Wenk. Total Award: $6200;
7/97-12/97.
NiCox Pharmaceutical, S.A., France, Investigation of a novel anti-inflammatory drug. P.I. Gary
Wenk. Total Award: $11,000. 11/97-4/98.
Parke-Davis Pharmaceutical Co., Unrestricted Gift, P.I. Gary Wenk. $12,000.
NiCox Pharmaceutical, S.A., France, Unrestricted Gift, P.I. Gary Wenk. $89,000.
Janssen Pharmaceutical Co., Unrestricted Gift, P.I. Gary Wenk. $55,000.
Parke-Davis Pharmaceutical Co., Unrestricted Gift, P.I. Gary Wenk. $22,000.
Wenk
53
Alzheimer's Disease and Related Disorders Association, IIRG-95-004, "Investigations of a
Novel Animal Model of Cholinergic Hypofunction," P.I.- Gary Wenk; Total Direct Costs:
$148,254; Percent of Time: 15%; 07/01/95 - 06/30/98.
Research for Rett Foundation, Neurochemical Investigations of Rett Syndrome, P.I.- Gary
Wenk, Total Direct Costs: $10,250; 07/01/97 - 06/30/99
National Institute of Child Health and Human Development, 1 RO3 HD 35462, Rett Syndrome:
Investigations of Cholinergic Function, P.I. - Gary Wenk; Total Direct Costs: $95,311; Percent of
time: 20%; 08/01/97 - 07/31/99.
Autism Research Foundation and The Stallone Fund for Autism Research Grant, Pathology of
cholinergic function in Autism. P.I. Gary Wenk. Total Award: $9573. 12/1/97 - 11/30/99.
National Institute of Aging, RO1 AG 10546, "Aging Vulnerability to Inflammatory Processes,"
P.I. -Gary Wenk; Total Direct Costs: $696,623; Percent of Time: 20%; 07/01/98 - 06/30/02.
Alzheimer's Association, IIRG-01-2654, "Neuroprotection of the consequences of amyloid and
presenilin overexpression," P.I.- Gary Wenk; Total Direct Costs: $239,943; Percent of Time:
18%; 09/01/01 - 08/31/04.
Office of National Drug Control Policy, Contract for RIA assays on melatonin in saliva, P.I. –
Richard Bootzin; Total Direct Costs: $3000.
National Institute Mental Health, “Aging and sites of action of cognition-enhancing drugs.” P.I.
Diana Woodruff-Pak, Co-P.I. –Gary Wenk; Total Direct Costs: $40,000; Percent Time: 5%;
12/01/03 -11/30/08.
Ohio State University, Population and Health Targeted Investment in Excellence, “Gene/
environmental interactions and functional connectivity in the cholinergic anti-inflammatory
pathway,” P.I. Thayer (Co-P.I., Wenk); Total Direct: $100,000; 07/01/2007- 12/31/2008.
National Institute of Aging, RO1 AG 10546, "Aging Vulnerability to Inflammatory Processes,"
P.I. -Gary Wenk; Total Direct Costs: $1,250,000; Percent of Time: 40%; 09/01/02 - 08/31/08.
Merz Pharmaceuticals., Frankfurt, Germany, "Evaluation of the anti-inflammatory abilities of
Memantine," P.I.- Gary Wenk; Total Award: $200,000. 7/2007-6/2009.
National Institute of Aging, RO1 AG 030331, "Aging microglia-neuronal communication," P.I. Gary Wenk; Total Direct Costs: $1,400,000; Percent of Time: 40%; 04/01/08 - 03/31/13.
National Institute of Aging, RO1 AG 037320, "Vulnerability to neuroinflammation of brainstem
ascending aminergic systems," P.I. -Gary Wenk; Total Direct Costs: $1,500,000; Percent of
Time: 40%; 09/01/11 - 06/30/16.
Wenk
Women & Philanthropy, The Ohio State University, “Understanding the mechanisms of brain
aging,” $38,500. June, 2012.
54